La compra nausil metoclopramide sin receta de interbet, martomide

Metoclopramide is used for short term treatment of gastroesophageal reflux disease (GERD) in certain patients who do not respond to other therapy. It is used to treat symptoms of a certain digestive problem in diabetic patients (diabetic gastroparesis). Metoclopramide is a gastrointestinal stimulant and antinauseant. It works by increasing the movement of the stomach and intestines to help move food and acid out of the stomach more quickly. It also works in certain areas in the brain to decrease nausea.

Use Metoclopramide as directed by your doctor.

Take Metoclopramide by mouth 30 minutes before meals unless directed otherwise by your doctor.

It may take several days to weeks for Metoclopramide to work. Do not stop taking Metoclopramide without checking with your doctor.

If you miss a dose of Metoclopramide, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Metoclopramide.

Store Metoclopramide at room temperature, between 68 and 77 degrees F (20 and 25 degrees C), in a tightly closed container. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Metoclopramide out of the reach of children and away from pets.

Do NOT use Metoclopramide if:

you are allergic to any ingredient in Metoclopramide

you have seizures (eg, epilepsy); bleeding, blockage, or perforation in your stomach or intestines; or tumors on your adrenal gland (pheochromocytoma)

you are taking cabergoline or pergolide

you are taking medicines, such as phenothiazines (eg, chlorpromazine), that may cause extrapyramidal reactions (abnormal, involuntary muscle movements of the head, neck, or limbs). Check with your doctor if you are unsure if any of your medicines may cause extrapyramidal reactions.

Contact your doctor or health care provider right away if any of these apply to you.

Some medical conditions may interact with Metoclopramide. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

if you are pregnant, planning to become pregnant, or are breast-feeding

if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

if you have allergies to medicines, foods, or other substances

if you have a history of mental or mood problems (eg, depression) or suicidal thoughts or actions

if you have a history of asthma, heart failure, high blood pressure, diabetes, Parkinson disease, blood problems (eg, porphyria), kidney problems, liver problems (eg, cirrhosis), breast cancer, or low levels of an enzyme called methemoglobin reductase

if you are taking another form of metoclopramide (eg, syrup, orally disintegrating tablet).

Some medicines may interact with Metoclopramide. Tell your health care provider if you are taking any other medicines, especially any of the following:

Monoamine oxidase inhibitors (MAOIs) (eg, phenelzine) because the risk of serious side effects (eg, high blood pressure, seizures) may be increased

Anticholinergic medicine (eg, hyoscyamine) or narcotic pain medicines (eg, codeine) because they may decrease Metoclopramide's effectiveness

Acetaminophen, benzodiazepines (eg, diazepam), cyclosporine, insulin, levodopa, phenothiazines (eg, chlorpromazine), sedatives (eg, zolpidem), selective serotonin reuptake inhibitors (SSRIs) (eg, fluoxetine), succinylcholine, or tetracycline because the risk of their side effects may be increased by Metoclopramide

Cabergoline, digoxin, or pergolide because their effectiveness may be decreased by Metoclopramide.

This may not be a complete list of all interactions that may occur. Ask your health care provider if Metoclopramide may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

Important safety information:

Metoclopramide may cause drowsiness or dizziness. These effects may be worse if you take it with alcohol or certain medicines. Use Metoclopramide with caution. Do not drive or perform other possible unsafe tasks until you know how you react to it.

Do not drink alcohol or use medicines that may cause drowsiness (eg, sleep aids, muscle relaxers) while you are using Metoclopramide without first checking with your doctor; it may add to their effects. Ask your pharmacist if you have questions about which medicines may cause drowsiness.

Do NOT take more than the recommended dose or use Metoclopramide for longer than 12 weeks without checking with your doctor.

Diabetes patients - Metoclopramide may affect your blood sugar. Check blood sugar levels closely. Ask your doctor before you change the dose of your diabetes medicine.

Tell your doctor or dentist that you take Metoclopramide before you receive any medical or dental care, emergency care, or surgery.

Neuroleptic malignant syndrome (NMS) is a possibly fatal syndrome that can be caused by Metoclopramide. Symptoms may include fever; stiff muscles; confusion; abnormal thinking; fast or irregular heartbeat; and sweating. Contact your doctor at once if you have any of these symptoms.

Some patients who take Metoclopramide may develop muscle movements that they cannot control. This is more likely to happen in elderly patients, especially women. The chance that this will happen or that it will become permanent is greater in those who take Metoclopramide in higher doses or for a long time. Muscle problems may also occur after short-term treatment with low doses. Tell your doctor at once if you have muscle problems with your arms; legs; or your tongue, face, mouth, or jaw (eg, tongue sticking out, puffing of cheeks, mouth puckering, chewing movements) while taking Metoclopramide.

Patients who take Metoclopramide may be at increased risk for new or worsening mental or mood changes (eg, depression) or suicidal thoughts or actions. Watch patients who take Metoclopramide closely. Contact the doctor at once if new, worsened, or sudden symptoms such as depressed mood or any unusual change in mood or behavior occur. Contact the doctor right away if any signs of suicidal thoughts or actions occur.

Metoclopramide may increase the amount of a certain hormone (prolactin) in your blood. Symptoms may include enlarged breasts, missed menstrual period, decreased sexual ability, or nipple discharge. Contact your doctor right away if you experience any of these symptoms.

Lab tests, including liver and kidney function tests, may be performed while you use Metoclopramide. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.

Use Metoclopramide with caution in the elderly; they may be more sensitive to its effects, especially drowsiness, confusion, and uncontrolled muscle movements, including tardive dyskinesia.

Metoclopramide should be used with extreme caution in children; safety and effectiveness in children have not been confirmed. The risk of developing uncontrolled muscle movements may be greater in children.

Pregnancy and breast feeding: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Metoclopramide while you are pregnant. Metoclopramide is found in breast milk. If you are or will be breast-feeding while you use Metoclopramide, check with your doctor. Discuss any possible risks to your baby.

A small number of patients have experienced withdrawal symptoms when stopping Metoclopramide. These symptoms may include dizziness, nervousness, and headache.

All medicines may cause side effects, but many people have no, or minor, side effects.

Check with your doctor if any of these most common side effects persist or become bothersome:

Decreased energy; diarrhea; dizziness; drowsiness; headache; nausea; restlessness; tiredness; trouble sleeping.

Seek medical attention right away if any of these severe side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; unusual hoarseness); abnormal thinking; confusion; dark urine; decreased balance or coordination; decreased sexual ability; fast, slow, or irregular heartbeat; fever; hallucinations; loss of bladder control; mental or mood changes (eg, depression, anxiety, agitation, jitteriness); seizures; severe or persistent dizziness, headache, or trouble sleeping; severe or persistent restlessness, including inability to sit still; shortness of breath; stiff or rigid muscles; sudden increased sweating; sudden, unusual weight gain; suicidal thoughts or actions; swelling of the arms, legs, or feet; uncontrolled muscle spasms or movements (eg, of the arms, legs, tongue, jaw, cheeks; twitching; tremors); vision changes; yellowing of the skin or eyes.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider.

Los clientes que compraron este producto tambien han comprado:

Prilosec $0.55 Por pastilla Prilosec is used for treating heartburn or irritation of the esophagus caused by gastroesophageal reflux disease (GERD). Mas informacion Ditropan $0.4 Por pastilla Ditropan is used for relieving symptoms of bladder problems (urinary urgency, frequency, or leakage; loss of bladder control; and painful urination) in certain patients. Mas informacion

Zantac $0.18 Por pastilla Zantac is used for treating certain conditions that cause your body to make too much stomach acid (eg, Zollinger-Ellison syndrome). Mas informacion Protonix $0.41 Por pastilla Protonix is indicated for the short-term treatment of erosive esophagitis associated with gastroesophageal reflux disease (GERD) Mas informacion

Allopurinol $0.75 Por pastilla Allopurinol is used for treating gout and to treat high uric acid levels in the blood or urine caused by certain types of cancer chemotherapy. Mas informacion Noroxin $0.43 Por pastilla Noroxin is used to treat bacterial infections of the prostate and urinary tract. Noroxin also treats gonorrhea. Mas informacion

Buy oxsoralen 10mg

Buy Oxsoralen Lotion 1% (10mg/ml) Online

Call Centre (sales, refill and order information): Monday to Friday - 7:00 am to 7:00 pm (Central Standard Time) Saturday - 8:00 am to 3:00 pm (Central Standard Time)

The Program and this Website are marketed by OMNI DWC LLC.

OMNI DWC LLC is incorporated under the laws of the UAE, and the Terms and Conditions of Service provide that all your dealings with are governed by the laws of the UAE.

OMNI DWC LLC as the provider of this Program forwards the information required by the pharmacy or pharmacies you have chosen to fill your order, but please note that OMNI DWC LLC is NOT a pharmacy and does NOT sell medications. The pharmacy that actually dispenses your prescription is solely responsible for the quality of goods and services that it provides.

Sale of the Product(s) between the pharmacy and you are completed in the jurisdiction in which the pharmacy operates. You become the owner of the Product when the pharmacy accepts your order for fulfillment, places the Product in a container or otherwise completes the steps necessary to prepare it for your use, and causes your payment to be processed. You are then responsible for personally importing the Product to your address in the jurisdiction in which you reside. Any steps connected with transportation are carried out by you or by someone acting as agent on your behalf.

All orders, including your first one, are governed by the latest version of our Terms and Conditions of Service. To be sure you understand those Terms and Conditions, please check our Website at Terms Of Service.

You confirm that you have received, read, understood and agree to accept our complete Terms and Conditions of Service each time you use services provided by OMNI DWC LLC directly or indirectly via its contracted call centres and or Websites.

Prices are shown in USD as of September 23, 2016. Subject to change. Some Products are not suitable for international delivery. By prescription only (RX). Return Policy: Due to the nature of the Products, Products are not returnable. All sales are final sales.

© 2016 OMNI DWC LLC

* Substitutes with the same active ingredient will be included in search results when available.

Oxsoralen-Ultra

CAUTION: METHOXSALEN IS A POTENT DRUG. READ ENTIRE BROCHURE PRIOR TO PRESCRIBING OR DISPENSING THIS MEDICATION.

Methoxsalen with UV radiation should be used only by physicians who have special competence in the diagnosis and treatment of psoriasis and who have special training and experience in photochemotherapy. The use of Psoralen and ultraviolet radiation therapy should be under constant supervision of such a physician. For the treatment of patients with psoriasis, photochemotherapy should be restricted to patients with severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis is certain. Because of the possibilities of ocular damage, aging of the skin, and skin cancer (including melanoma), the patient should be fully informed by the physician of the risks inherent in this therapy.

CAUTION: Oxsoralen-Ultra ® (Methoxsalen Soft Gelatin Capsules) should not be used interchangeably with regular Oxsoralen ® or 8-MOP ® (Methoxsalen Hard Gelatin Capsules). This new dosage form of methoxsalen exhibits significantly greater bioavailability and earlier photosensitization onset time than previous methoxsalen dosage forms. Patients should be treated in accordance with the dosimetry specifically recommended for this product. The minimum phototoxic dose (MPD) and phototoxic peak time after drug administration prior to onset of photochemotherapy with this dosage form should be determined.

I. DESCRIPTION

Oxsoralen-Ultra (methoxsalen capsules, USP) contains 10 mg. methoxsalen (8-methoxsalen). Methoxsalen occurs as white to pale yellow crystals and can be obtained naturally from seeds of Ammi majus and roots of Heracleum Candicans or through synthesis. Methoxsalen is practically insoluble in water, freely soluble in chloroform, soluble in boiling alcohol, in acetone, in acetic acid, in propylene glycol, and in benzene, sparingly soluble in boiling water and in ether. The chemical name of methoxsalen is 9-methoxy-7H-furo [3,2-g] [1] benzopyran-7-one; its empirical formula is C 12 H 8 O 4 and the molecular weight is 216.19. The structural formula is:

Oxsoralen-Ultra is available as soft gelatin capsules containing the following inactive ingredients: polyethylene glycol 400, sorbital special, gelatin, glycerin, water, titanium dioxide, methyl & propylparaben, D&C yellow 10, FD&C blue 1, FD&C yellow 6.

II. CLINICAL PHARMACOLOGY

The combination treatment regimen of psoralen (P) and ultraviolet radiation of 320-400 nm wavelength commonly referred to as UVA is known by the acronym, PUVA. Skin reactivity to UVA (320-400 nm) radiation is markedly enhanced by the ingestion of methoxsalen. In a well controlled bioavailability study, Oxsoralen-Ultra Capsules reached peak drug levels in the blood of test subjects between 0.5 and 4 hours (Mean = 1.8 hours) as compared to between 1.5 and 6 hours (Mean = 3.0 hours) for regular Oxsoralen when administered with 8 ounces of milk. Peak drug levels were 2 to 3 fold greater when the overall extent of drug absorption was approximately two fold greater for Oxsoralen-Ultra Capsules as compared to regular Oxsoralen Capsules. Detectable methoxsalen levels were observed up to 12 hours post dose. The drug half-life is approximately 2 hours. Photosensitivity studies demonstrate a shorter time of peak photosensitivity of 1.5 to 2.1 hours vs. 3.9 to 4.25 hours for regular Oxsoralen capsules. In addition, the mean minimal erythema dose (MED), J/cm 2. for the Oxsoralen-Ultra Capsules is substantially less than that required for regular Oxsoralen Capsules (Levins et al. 1984 and private communication 1 ).

Methoxsalen is reversibly bound to serum albumin and is also preferentially taken up by epidermal cells (Artuc et al. 1979 2 ). At a dose which is six times larger than that used in humans, it induces mixed function oxidases in the liver of mice (Mandula et al. 1978 3 ). In both mice and man, methoxsalen is rapidly metabolized. Approximately 95% of the drug is excreted as a series of metabolites in the urine within 24 hours (Pathak et al. 1977 4 ). The exact mechanism of action of methoxsalen with the epidermal melanocytes and keratinocytes is not known. The best known biochemical reaction of methoxsalen is with DNA. Methoxsalen, upon photoactivation, conjugates and forms covalent bonds with DNA which leads to the formation of both monofunctional (addition to a single strand of DNA) and bifunctional (crosslinking of psoralen to both strands of DNA) adducts (Dall’ Acqua et al. 1971 5 ; Cole, 1970 6 ; Musajo et al. 1974 7 ; Dall’ Acqua et al. 1979 8 ). Reactions with proteins have also been described (Yoshikawa, et al. 1979 9 ).

Methoxsalen acts as a photosensitizer. Administration of the drug and subsequent exposure to UVA can lead to cell injury. Orally administered methoxsalen reaches the skin via the blood and UVA penetrates well into the skin. If sufficient cell injury occurs in the skin, an inflammatory reaction occurs. The most obvious manifestation of this reaction is delayed erythema, which may not begin for several hours and peaks at 48-72 hours. The inflammation is followed, over several days to weeks, by repair which is manifested by increased melanization of the epidermis and thickening of the stratum corneum. The mechanisms of therapy are not known. In the treatment of psoriasis, the mechanism is most often assumed to be DNA photodamage and resulting decrease in cell proliferation but other vascular, leukocyte, or cell regulatory mechanisms may also be playing some role. Psoriasis is a hyper-proliferative disorder and other agents known to be therapeutic for psoriasis are known to inhibit DNA synthesis.

III. INDICATIONS AND USAGE

Photochemotherapy (Methoxsalen with long wave UVA radiation) is indicated for the symptomatic control of severe, recalcitrant, disabling psoriasis not adequately responsive to other forms of therapy and when the diagnosis has been supported by biopsy. Methoxsalen is intended to be administered only in conjunction with a schedule of controlled doses of long wave ultraviolet radiation.

IV. CONTRAINDICATIONS

A. Patients exhibiting idiosyncratic reactions to psoralen compounds.

B. Patients possessing a specific history of light sensitive disease states should not initiate methoxsalen therapy except under special circumstances. Diseases associated with photosensitivity include lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, and albinism.

C. Patients with melanoma or with a history of melanoma.

D. Patients with invasive squamous cell carcinomas.

E. Patients with aphakia, because of the significantly increased risk of retinal damage due to the absence of lenses.

V. WARNINGS - GENERAL

A. SKIN BURNING: Serious burns from either UVA or sunlight (even through window glass) can result if the recommended dosage of the drug and/or exposure schedules are exceeded.

ANIMAL STUDIES: Topical or intraperitoneal methoxsalen has been reported to be a potent photocarcinogen in albino mice and hairless mice (Hakim et al. 1960 10 ). However, methoxsalen given by the oral route to Swiss albino mice suggests this agent exerts a protective effect against ultraviolet carcinogenesis; mice given 8-methoxypsoralen in their diet showed 38% ear tumors 180 days after the start of ultraviolet therapy compared to 62% for controls (O’Neal et al. 1957 11 ).

HUMAN STUDIES: A 5.7 year prospective study of 1380 psoriasis patients treated with oral methoxsalen and ultraviolet A photochemotherapy (PUVA) demonstrated that the risk of cutaneous squamous-cell carcinoma developing at least 22 months following the first PUVA exposure was approximately 12.8 times higher in the high dose patients than in the low dose patients (Stern et al. 1979 12. Stern et al. 1980 13. and Stern et al. 1984 14 ). The substantial dose-dependent increase was observed in patients with neither a prior history of skin cancer nor significant exposure to cutaneous carcinogens. Reduction in PUVA dosage significantly reduces the risk. No substantial dose related increase was noted for basal cell carcinoma according to Stern et al. 1984 14. Increases appear greatest in patients who have pre-PUVA exposure to 1) prolonged tar and UVB treatment, 2) ionizing radiation, or 3) arsenic. Roenigk et al. 1980 15. studied 690 patients for up to 4 years and found no increase in the risk of non-melanoma skin cancer, although patients in this cohort had significantly less exposure to PUVA than in the Stern et al. study. Recent analysis of new data in the Stern et al cohort (Stern et al. 1997 16 ) has shown that these patients had an elevated relative risk of contracting melanoma. The relative risk for melanoma in these patients was 2.3 (95 percent confidence interval 1.1 to 4.1). The risk is particularly higher in those patients who have received more than 250 PUVA treatments and in those whose treatment has spanned greater than 15 years earlier. Some patients developing melanoma did so even after having ceased PUVA therapy over 5 years earlier. These observations indicate the need for monitoring of PUVA patients for skin tumors throughout their lives. In a study in Indian patients treated for 4 years for vitiligo, 12 percent developed keratoses, but not cancer, in the depigmented, vitiliginous areas (Mosher, 1980 17 ). Clinically, the keratoses were keratotic papules, actinic keratosis-like macules, nonscaling dome-shaped papules, and lichenoid porokeratotic-like papules.

ANIMAL STUDIES: Exposure to large doses of UVA causes cataracts in animals, and this effect is enhanced by the administration of methoxsalen (Cloud et al. 1960 18 ; Cloud et al. 1961 19 ; Freeman et al. 1969 20 ).

HUMAN STUDIES: It has been found that the concentration of methoxsalen in the lens is proportional to the serum level. If the lens is exposed to UVA during the time methoxsalen is present in the lens, photochemical action may lead to irreversible binding of methoxsalen to proteins and the DNA components of the lens (Lerman et al. 1980 21 ). However, if the lens is shielded from UVA, the methoxsalen will diffuse out of the lens in a 24 hour period (Lerman et al. 1980 21 ). Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for the twenty-four (24) hour period following ingestion of methoxsalen whether exposed to direct or indirect sunlight in the open or through a window glass. Among patients using proper eye protection, there is no evidence for a significantly increased risk of cataracts in association with PUVA therapy (Stern et al. 1979 12 ). Thirty-five of 1380 patients have developed cataracts in the five years since their first PUVA treatment. This incidence is comparable to that expected in a population of this size and age distribution. No relationship between PUVA dose and cataract risk in this group has been noted.

D. ACTINIC DEGENERATION: Exposure to sunlight and/or ultraviolet radiation may result in “premature aging” of the skin.

E. BASAL CELL CARCINOMAS: Patients exhibiting multiple basal cell carcinomas or having a history of basal cell carcinomas should be diligently observed and treated.

F. RADIATION THERAPY: Patients having a history of previous x-ray therapy or grenz ray therapy should be diligently observed for signs of carcinoma.

G. ARSENIC THERAPY: Patients having a history of previous arsenic therapy should be diligently observed for signs of carcinoma.

H. HEPATIC DISEASES: Patients with hepatic insufficiency should be treated with caution since hepatic biotransformation is necessary for drug urinary excretion.

I. CARDIAC DISEASES: Patients with cardiac diseases or others who may be unable to tolerate prolonged standing or exposure to heat stress should not be treated in a vertical UVA chamber.

J. ELDERLY PATIENTS: Caution should be used in elderly patients, especially those with a pre-existing history of cataracts, cardiovascular conditions, kidney and/or liver dysfunction, or skin cancer.

K. TOTAL DOSAGE: The total cumulative dose of UVA that can be given over long periods of time with safety has not as yet been established.

L. CONCOMITANT THERAPY: Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, fluoroquinolone antibiotics, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal, and methyl orange.

VI. PRECAUTIONS

A. GENERAL - APPLICABLE TO PSORIASIS TREATMENT:

BEFORE METHOXSALEN INGESTION Patients must not sunbathe during the 24 hours prior to methoxsalen ingestion and UV exposure. The presence of a sunburn may prevent an accurate evaluation of the patient’s response to photochemotherapy.

AFTER METHOXSALEN INGESTION

UVA-absorbing wrap-around sunglasses should be worn during daylight for 24 hours after methoxsalen ingestion. The protective eyewear must be designed to prevent entry of stray radiation to the eyes, including that which may enter from the sides of the eyewear. The protective eyewear is used to prevent the irreversible binding of methoxsalen to the proteins and DNA components of the lens. Cataracts form when enough of the binding occurs. Visual discrimination should be permitted by the eyewear of patient well-being and comfort.

Patients must avoid sun exposure, even through window glass or cloud cover, for at least 8 hours after methoxsalen ingestion. If sun exposure cannot be avoided, the patient should wear protective devices such as a hat and gloves, and/or apply sunscreens which contain ingredients that filter out UVA radiation (e. g. sunscreens containing benzophenone and/or PABA esters which exhibit a sun protective factor equal to or greater than 15). These chemical sunscreens should be applied to all areas that might be exposed to the sun (including lips). Sunscreens should not be applied to areas affected by psoriasis until after the patient has been treated in the UVA chamber.

DURING PUVA THERAPY

Total UVA-absorbing/blocking goggles mechanically designed to give maximal ocular protection must be worn. Failure to do so may increase the risk of cataract formation. A reliable radiometer can be used to verify elimination of UVA transmission through the goggles.

Abdominal skin, breasts, genitalia, and other sensitive areas should be protected for approximately 1/3 of the initial exposure time until tanning occurs.

Unless affected by disease, male genitalia should be shielded.

AFTER COMBINED METHOXSALEN/UVA THERAPY

UVA-absorbing wrap-around sunglasses should be worn during daylight for 24 hours after combined methoxsalen/UVA therapy.

Patients should not sunbathe for 48 hours after therapy. Erythema and/or burning due to photochemotherapy and sunburn due to sun exposure are additive.

B. INFORMATION FOR PATIENTS:

See accompanying Patient Package Insert.

C. LABORATORY TESTS:

Patients should have an ophthalmologic examination prior to start of therapy, and thence yearly.

Patients should have routine laboratory tests prior to the start of therapy and at regular periods thereafter if patients are on extended treatments.

D. DRUG INTERACTIONS:

E. CARCINOGENESIS:

F. PREGNANCY:

Pregnancy Category C. Animal reproduction studies have not been conducted with methoxsalen. It is also not known whether methoxsalen can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Methoxsalen should be given to a woman with reproductive capacity only if clearly needed.

G. NURSING MOTHERS:

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, either methoxsalen ingestion or nursing should be discontinued.

H. PEDIATRIC USE:

Safety in children has not been established. Potential hazards of long-term therapy include the possibilities of carcinogenicity and cataractogenicity as described in the Warnings Section as well as the probability of actinic degeneration which is also described in the Warnings Section.

I. GERIATRIC USE:

Clinical studies with Oxsoralen-Ultra capsules did not include sufficient numbers of subjects aged 65 and over to determine whether elderly subjects responded differently from younger subjects. Other reported clinical experience has not identified differences in response between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

VII. ADVERSE REACTIONS

The most commonly reported side effect of methoxsalen alone is nausea, which occurs with approximately 10% of all patients. This effect may be minimized or avoided by instructing the patient to take methoxsalen in milk or food, or to divide the dose into two portions, taken approximately one-half hour apart. Other effects include nervousness, insomnia, and depression.

B. COMBINED METHOXSALEN/UVA THERAPY:

PRURITUS: This adverse reaction occurs with approximately 10% of all patients. In most cases, pruritus can be alleviated with frequent application of bland emollients or other topical agents; severe pruritus may require systemic treatment. If pruritus is unresponsive to these measures, shield pruritic areas from further UVA exposure until the condition resolves. If intractable pruritus is generalized, UVA treatment should be discontinued until the pruritus disappears.

ERYTHEMA: Mild, transient erythema at 24-48 hours after PUVA therapy is an expected reaction and indicates that a therapeutic interaction between methoxsalen and UVA occurred. Any area showing moderate erythema (greater than Grade 2 - See Table 1 for grades of erythema) should be shielded during subsequent UVA exposures until the erythema has resolved. Erythema greater than Grade 2 which appears within 24 hours after UVA treatment may signal a potentially severe burn. Erythema may become progressively worse over the next 24 hours, since the peak erythemal reaction characteristically occurs 48 hours or later after methoxsalen ingestion. The patient should be protected from further UVA exposures and sunlight, and should be monitored closely.

IMPORTANT DIFFERENCES BETWEEN PUVA ERYTHEMA AND SUNBURN: PUVA-induced inflammation differs from sunburn or UVB phototherapy in several ways. The percent transmission of UVB varies between 0% to 34% through skin whereas UVA varies between 1% to 80% transmission; thus, UVA is transmitted to a larger percent through the skin. (Diffey, 1982 22 ). The DNA lesions induced by PUVA are very different from UV-induced thymine dimers and may lead to a DNA crosslink. This DNA lesion may be more problematic to the cell because crosslinks are more lethal and psoralen-DNA photoproducts may be “new” or unfamiliar substrates for DNA repair enzymes. DNA synthesis is also suppressed longer after PUVA. The time course of delayed erythema is different with PUVA and may not involve the usual mediators seen in sunburn. PUVA-induced redness may be just beginning at 24 hours, when UVB erythema has already passed its peak. The erythema dose-response curve is also steeper for PUVA. Compared to equally erythemogenic doses of UVB, the histologic alterations induced by PUVA show more dermal vessel damage and longer duration of epidermal and dermal abnormalities.

OTHER ADVERSE REACTIONS: Those reported include edema, dizziness, headache, malaise, depression, hypopigmentation, vesiculation and bullae formation, non-specific rash, herpes simplex, miliaria, urticaria, folliculitis, gastrointestinal disturbances, cutaneous tenderness, leg cramps, hypotension, and extension of psoriasis.

VIII. OVERDOSAGE

In the event of methoxsalen overdosage, induce emesis and keep the patient in a darkened room for at least 24 hours. Emesis is most beneficial within the first 2 to 3 hours after ingestion of methoxsalen, since maximum blood levels are reached by this time.

IX. DRUG DOSAGE & ADMINISTRATION

CAUTION: Oxsoralen-Ultra represents a new dose form of methoxsalen. This new dosage form of methoxsalen exhibits significantly greater bioavailability and earlier photosensitization onset time than previous methoxsalen dosage forms. Each patient should be evaluated by determining the minimum phototoxic dose (MPD) and phototoxic peak time after drug administration prior to onset of photochemotherapy with this dosage form. Human bioavailability studies have indicated the following drug dosage and administration directions are to be used as a guideline only.

1. DRUG DOSAGE - INITIAL THERAPY: The methoxsalen capsules should be taken 1 1/2 to 2 hours before UVA exposure with some low fat food or milk according to the following table:

Elderly patients should generally be started at the low end of the dose recommended according to body weight and closely monitored during PUVA therapy. Although clinical experience has not identified differences in response between elderly and younger patients, the use of methoxsalen in older individuals may be affected by the presence or pre-existing medical conditions.

2. INITIAL EXPOSURE: The initial UVA exposure energy level and corresponding time of exposure is determined by the patient’s skin characteristics for sun burning and tanning as follows:

(*Patients with natural pigmentation of these types should be classified into a lower skin type category if the sunburning history so indicates.)

Recommended Joules/cm 2

Always burn, never tan (patients with erythrodermic psoriasis are to be classed as Type I for determination of UVA dosage.)

If the MPD is done, start at 1/2 MPD.

Additional drug dosage directions are as follows:

Weight Change: In the event that the weight of a patient changes during treatment such that he/she falls into an adjacent weight range/dose category, no change in the dose of methoxsalen is usually required. If, in the physician’s opinion, however, a weight change is sufficiently great to modify the drug dose, then an adjustment in the time of exposure to UVA should be made.

Dose/Week: The number of doses per week of methoxsalen capsules will be determined by the patient’s schedule of UVA exposures. In no case should treatments be given more often than once every other day because the full extent of phototoxic reactions may not be evident until 48 hours after each exposure.

Dosage Increase: Dosage may be increased by 10 mg. after the fifteenth treatment under the conditions outlined in section XI. B.4.b.

X. UVA RADIATION SOURCE SPECIFICATIONS & INFORMATION

A. IRRADIANCE UNIFORMITY:

The following specifications should be met with the window of the detector held in a vertical plane:

Vertical variation: For readings taken at any point along the vertical center axis of the chamber (to within 15 cm from the top and bottom), the lowest reading should not be less than 70 percent of the highest reading.

Horizontal variation: Throughout any specific horizontal plane, the lowest reading must be at least 80 percent of the highest reading, excluding the peripheral 3 cm of the patient treatment space.

B. PATIENT SAFETY FEATURES:

The following safety features should be present: (1) Protection from electrical hazard: All units should be grounded and conform to applicable electrical codes. The patient or operator should not be able to touch any live electrical parts. There should be ground fault protection. (2) Protective shielding of lamps: The patient should not be able to come in contact with the bare lamps. In the event of lamp breakage, the patient should not be exposed to broken lamp components. (3) Hand rails and hand holds: Appropriate supports should be available to the patient. (4) Patient viewing window: A window which blocks UV should be provided for viewing the patient during treatment. (5) Door and latches: Patients should be able to open the door from the inside with only slight pressure to the door. (6) Non-skid floor: The floor should be of a non-skid nature. (7) Thermoregulation: Sufficient air flow should be provided for patient safety and comfort, limiting temperature within the UVA radiator cabinet to approximately less than 100° F. (8) Timer: The irradiator should be equipped with an automatic timer which terminates the exposure at the conclusion of a pre-set time interval. (9) Patient alarm device: An alarm device within the UVA irradiator chamber should be accessible to the patient for emergency activation. (10) Danger label: The unit should have a label prominently displayed which reads as follows:

DANGER - Ultraviolet Radiation - Follow your physician’s instructions - Failure to use protective eyewear may result in eye injury.

C. UVA EXPOSURE DOSIMETRY MEASUREMENTS:

The maximum radiant exposure or irradiance (within ± 15 percent) of UVA (320-400 nm) delivered to the patient should be determined by using an appropriate radiometer calibrated to be read in Joules/cm 2 or mW/cm 2. In the absence of a standard measuring technique approved by the National Bureau of Standards, the system should use a detector corrected to a cosine spatial response. The use and recalibration frequency of such a radiometer for a specific UVA irradiator chamber should be specified by the manufacturer because the UVA dose (exposure) is determined by the design of the irradiator, the number of lamps, and the age of the lamp. If irradiance is measured, the radiometer reading in mW/cm 2 is used to calculate the exposure time in minutes to deliver the required UVA in Joules/cm 2 to a patient in the UVA irradiator cabinet. The equation is:

Overexposure due to human error should be minimized by using an accurate automatic timing device, which is set by the operator and controlled by energizing and de-energizing the UVA irradiator lamp. The timing device calibration interval should be specified by the manufacturer. Safety systems should be included to minimize the possibility of delivering a UVA exposure which exceeds the prescribed dose, in the event the timer or radiometer should malfunction.

D. UVA SPECTRAL OUTPUT DISTRIBUTION:

The spectral distributions of the lamps should meet the following specifications:

1 As a percentage of total irradiance between 320 and 400 nanometers.

XI. PUVA TREATMENT PROTOCOL

The Oxsoralen-Ultra ® Capsules reach their maximum bioavailability in 1 1/2 to 2 hours after ingestion.

On average, the serum level achieved with Oxsoralen-Ultra is twice that obtained with 8-MOP (formerly Oxsoralen) and reach their peak concentration in less than 1/2 the time of the 8-MOP capsules.

As a result the mean MED J/cm 2 for the Oxsoralen-Ultra Capsules is substantially less than that required for 8-MOP (Levins et al. 1984 and private communication 1 ).

Photosensitivity studies demonstrate a shorter time of peak photosensitivity of 1.5 to 2.1 hours vs. 3.9 to 4.25 hours for regular methoxsalen capsules.

A. INITIAL EXPOSURE: The initial UVA exposures should be conducted according to the guidelines presented previously under IX. Psoriasis Therapy, Drug Dosage-Initial Therapy and Initial Exposure.

B. CLEARING PHASE: Specific recommendations for patient treatment are as follows:

SKIN TYPES I, II, & III. Patients with skin types I, II, and III may be treated 2 or 3 times per week. UVA exposure may be held constant or increased by up to 1.0 Joule/cm 2 at each treatment, according to the patient’s response. If erythema occurs, however, do not increase exposure time until erythema resolves. The severity and extent of the patient’s erythema may be used to determine whether the next exposure should be shortened, omitted, or maintained at the previous dosage. See Adverse Reactions section for additional information.

SKIN TYPES IV, V, & VI. Patients with skin types IV, V, and VI may be treated 2 or 3 times per week. UVA exposure may be held constant or increased by up to 1.5 Joules/cm 2 at each treatment unless erythema occurs. If erythema occurs, follow instructions outlined above in the procedures for patients with skin types I, II, and III.

ERYTHRODERMIC PSORIASIS. Patients with erythrodermic psoriasis should be treated with special attention because pre-existing erythema may obscure observations of possible treatment-related phototoxic erythema. These patients may be treated 2 or 3 times per week, as a Type I patient.

If there is no response after a total of 10 treatments, the exposure of UVA energy may be increased by an additional 0.5-1.0 Joules/cm 2 above the prior incremental increases for each treatment. (Example: a patient whose exposure dosage is being increased by 1.0 Joule/cm 2 may now have all subsequent doses increased by 1.5-2.0 Joules/cm 2 .)

If there is no response, or only minimal response, after 15 treatments, the dosage of methoxsalen may be increased by 10 mg (a one-time increase in dosage). This increased dosage may be continued for the remainder of the course of treatment but should not be exceeded.

If a patient misses a treatment, the UVA exposure time of the next treatment should not be increased. If more than one treatment is missed, reduce the exposure by 0.5 Joules/cm 2 for each treatment missed.

If the lower extremities are not responding as well as the rest of the body and do not show erythema, cover all other body areas and give 25 percent of the present exposure dose as an additional exposure to the lower extremities. This additional exposure to the lower extremities should be terminated if erythema develops on these areas.

Non-responsive psoriasis: If a patient’s generalized psoriasis is not responding, or if the condition appears to be worsening during treatment, the possibility of a generalized phototoxic reaction should be considered. This may be confirmed by the improvement of the condition following temporary discontinuance of this therapy for two weeks. If no improvement occurs during the interruption of treatment, this patient may be considered a treatment failure.

C. ALTERNATIVE EXPOSURE SCHEDULE:

As an alternative to increasing the UVA exposure at each treatment, the following schedule may be followed; this schedule may reduce the total number of Joules/cm 2 received by the patient over the entire course of therapy.

Incremental increases in UVA exposure for all patients may range from 0.5 to 1.5 Joules/cm 2. according to the patient’s response to therapy.

Once Grade 2 clearing (see Table 2 ) has been reached and the patient is progressing adequately, UVA dosage is held constant. This dosage is maintained until Grade 4 clearing is reached.

If the rate of clearing significantly decreases, exposure dosage may be increased at each treatment (0.1-1.5 Joules/cm 2 ) until Grade 3 clearing and a satisfactory progress rate is attained. The UVA exposure will be held constant again until Grade 4 clearing is attained. These increases may be used also if the rate of clearing significantly decreases between Grade 3 and Grade 4 response. However, the possibility of a phototoxic reaction should be considered; see Non-responsive Psoriasis, above.

In summary, this schedule raises slightly the increments (Joules/cm 2 ) of UVA dosage, but limits these increases to those periods when the patient is not responding adequately. Otherwise, the UVA exposure is held at the lowest effective dose.

D. MAINTENANCE PHASE:

The goal of maintenance treatment is to keep the patient as symptom-free as possible with the least amount of UVA exposure.

SCHEDULE OF EXPOSURES: When patients have achieved 95 percent clearing, or Grade 4 response (Table 2 ), they may be placed on the following maintenance schedules (M 1 - M 4 ), in sequence. It is recommended that each maintenance schedule be adhered to for at least 2 treatments (unless erythema or psoriatic flare occurs, in which case see (2a) and (2b) below).

XII. HOW SUPPLIED

Oxsoralen-Ultra Capsules, each containing 10 mg of methoxsalen (8-methoxypsoralen) are available in green soft gelatin capsules in white plastic bottles of 50 (NDC 0187-0650-42), with VRX imprinted on one side of the capsule and 650 imprinted on the other side.

Store at 25°C (77°F); excursions permitted to 15°C - 30°C (59°F - 86°F).

BIBLIOGRAPHY

Levins, P. C. Gange, R. W. Momtaz-T, K. Parrish, J. A. and Fitzpatrick, T. B. A New Liquid Formulation of 8-Methoxypsoralen: Bioactivity and Effect of Diet: JID, 82. No. 2, pp. 185-187 (1984) and private communication.

Artuc, M. Stuettgen, G. Schalla, W. Schaefer, H. and Gazith, J. Reversible binding of 5-and 8-methoxypsoralen to human serum proteins (albumin) and to epidermis in vitro: Brit. J. Dermat. 101. pp. 669-677 (1979).

Mandula, B. B. Pathak, M. A. Nakayama, T. and Davidson, S. J. Induction of mixed-function oxidases in mouse liver by psoralens. Ibid, 99. pp. 687-692 (1978).

Pathak, M. A. Fitzpatrick, T. B. Parrish, J. A. PSORIASIS, Proceedings of the Second International Symposium. Edited by E. M. Farber, A. J. Cox, Yorke Medical Books, pp. 262-265 (1977).

Dall’Acqua, F. Marciani, S. Ciavatta, L. Rodighiero, G. Formation of interstrand cross-linkings in the photoreactions between furocoumarins and DNA; Z Naturforsch (B), 26. pp. 561-569 (1971).

Cole, R. S. Light-induced cross-linkings of DNA in the presence of a furocoumarin (psoralen), Biochem. Biophys. Acta, 217. pp. 30-39 (1970).

Musajo, L. Rodighiero, G. Caporale, G. Dall’Acqua, F. Marciani, S. Bordin, F. Baccichetti, F. Bevilacqua, R. Photoreactions between Skin-Photosensitizing Furocoumarins and Nucleic Acids, Sunlight and Man ; Normal and Abnormal Photobiologic Responses. Edited by M. A. Pathak, L. C. Harber, M. Seiji et al. University of Tokyo Press, pp. 369-387 (1974).

Dall’Acqua, F. Vedaldi, D. Bordin, F. and Rodighiero, G. New studies in the interaction between 8-methoxypsoralen and DNA in vitro ; JID, 73. pp. 191-197 (1979).

Yoshikawa, K. Mori, N. Sakakibara, S. Mizuno, N. Song, P. Photo Conjugation of 8-methoxypsoralen with Proteins; Photochem. & Photobiol. 29. pp. 1127-1133 (1979).

Hakim, R. D. Griffin, A. C. Knox, J. M. Erythema and tumor formation in methoxsalen treated mice exposed to fluorescent light; Arch. Dermatol. 82. pp. 572-577 (1960).

O’Neal, M. A. Griffin, A. C. The Effect of Oxypsoralen upon Ultraviolet Carcinogenesis in Albino Mice, Cancer Res. 17. pp. 911-916 (1957).

Stern, R. S. Unpublished personal communication.

Stern, R. S. Parrish, J. A. Zierler, S. Skin Carcinoma in Patients with Psoriasis Treated with Topical Tar and Artificial Ultraviolet Radiation. Lancet, 1. pp. 732-735 (1980).

Stern, R. S. Laird, N. Melski, J. Parrish, J. A. Fitzpatrick, T. B. Bleich, H. L. Cutaneous Squamous-Cell Carcinoma in Patients Treated with PUVA: NEJM, 310. No. 18, pp. 1156-1161 (1984).

Roenigk, Jr. H. H. and 12 Cooperating Investigators: Skin Cancer in the PUVA-48 Cooperative Study of Psoriasis. Program for Forty-First Annual Meeting for The Society of Investigative Dermatology, Inc. Sheraton Washington Hotel, Washington, D. C. May 12, 13, and 14, 1980. Abstracts JID, 74. No. 4, p. 250 (April, 1980).

Stern et al. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-up Study. New England Journal of Medicine, 336:1041-1045, (April 10, 1997).

Mosher, D. B. Pathak, M. A. Harris, T. J. Fitzpatrick, T. B. Development of Cutaneous Lesions in Vitiligo During Long-Term PUVA Therapy. Program for Forty-First Annual Meeting for The Society for Investigative Dermatology, Inc. Sheraton Washington Hotel, Washington, D. C. May 12, 13, and 14, 1980. Abstracts JID, 74. No. 4, p. 259 (April, 1980).

Cloud, T. M. Hakim, R. Griffin, A. C. Photosensitization of the eye with methoxsalen. I. Acute effects; Arch. Ophthalmol. 64. pp. 346-352 (1960).

Cloud, T. M. Hakim, R. Griffin, A. C. Photosensitization of the eye with methoxsalen. II. Chronic effects, Ibid, 66. pp. 689-694 (1961).

Freeman, R. G. Troll, D. Photosensitization of the eye by 8-methoxypsoralen, JID, 53. pp. 449-453 (1969).

Lerman, S. Megaw, J. Willis, I. Potential ocular complications from PUVA therapy and their prevention; JID 74. pp. 197-199 (1980).

Diffey, B. L. Medical Physics Handbook 11, Ultraviolet Radiation In Medicine, Adam Hilger, Ltd. Bristol, p. 86 (1982).

Manufactured for: Valeant Pharmaceuticals North America LLC Bridgewater, NJ 08807 USA

By: Heritage Pharma Labs Inc. East Brunswick, NJ 08816 USA

Rev. 02/15 9436102 51U000000155US02

PATIENT INFORMATION ON THE USE OF Oxsoralen-Ultra ® CAPSULES (METHOXSALEN, 10 mg) IN THE TREATMENT OF PSORIASIS

This brochure is intended to provide you with information about the treatment of psoriasis. The entire brochure should be read so that you are aware of the requirements on your part to ensure the effectiveness and safety of the therapy. Any additional questions that you may have can be answered by your doctor or pharmacist. In addition, the pharmacist will have a copy of a very technical brochure entitled the “Physician’s Package Insert” that you may wish to read. A. What is Oxsoralen-Ultra (Methoxsalen)? Oxsoralen-Ultra (methoxsalen) is a drug which has been shown to be effective in the treatment of psoriasis when combined with exposure to a very specific kind of light. The use of the drug must be combined with exposure to the special light to product effective therapy. Oxsoralen-Ultra represents a new dose form of methoxsalen. This new dosage form of methoxsalen exhibits significantly greater bioavailability and earlier photosensitization onset time than previous methoxsalen dosage forms. B. What is The Special Light? Light is classified into many different parts. One part is known as ultraviolet light, which is a normal component of sunlight. Artificial or man-made light sources are now available that produce the special part of light (ultraviolet “A”) necessary for the most effective therapy. C. What is “PUVA”? “PUVA” is the name of the treatment for psoriasis and stands for the use of Psoralen drug (Oxsoralen-Ultra) in combination with UltraViolet A light. D. What is Psoriasis? Psoriasis is a skin condition associated with red and scaly patches. The cause of psoriasis is not known. PUVA (Oxsoralen-Ultra with ultraviolet A light) is used for the treatment of severe psoriasis that has not been helped by other methods of therapy. E. What Should The Patient Do Before PUVA Therapy? Certain other medicines can make you more sensitive to the combination drug and light treatment. In addition, certain other medical conditions can be aggravated by this treatment. Before starting treatment, be sure to tell your doctor if you have experienced any of the following: 1. had a severe reaction to Oxsoralen-Ultra in the past 2. had recent x-ray treatment or planning any 3. have or ever have had skin cancer 4. have or ever have had any eye problems such as cataracts or loss of the lens of the eyes 5. have or ever have had liver problems 6. have or ever have had heart or blood pressure problems 7. have any medical condition that requires you to stay out of the sun such as lupus erythematosus 8. are taking any drugs (either prescription or nonprescription). Some drugs can increase your sensitivity to ultraviolet light either from the sun or man-made sources. Examples of such drugs include major tranquilizers, sulfa drugs for the treatment of infection or diabetes, tetracycline, antibiotics, griseofulvin products, thiazide-containing diuretics (blood pressure or water elimination drugs), and certain antibacterial or deodorant soaps. F. How Should The Patient Take Oxsoralen-Ultra? 1. The number of capsules recommended by your doctor should be taken with some food or lowfat milk two hours before ultraviolet light treatment. 2. Oxsoralen-Ultra is a potent drug. Never take more than is prescribed for you since it may result in burning and/or blistering of your skin after exposure to ultraviolet light. G. What Precautions Should Be Taken During And After PUVA Therapy? 1. Eye Protection – Make sure that you wear special wrap-around sunglasses that totally block or absorb ultraviolet light. Put them on immediately after taking Oxsoralen-Ultra and continue wearing them for 24 hours if any light is present (even if indirect such as reflection or through window glass). Ordinary sunglasses are not adequate. 2. Skin & Lip Protection – Do not allow exposure of your skin and lips to sunlight for 8 hours after treatment. In addition, do not expose your skin to either sunlight or sun lamps (regardless of safety claims) within 24 hours of a scheduled treatment. It is advisable to wear protective clothing (hat, gloves) to cover as much of your body as possible after treatment as well as using a sun screen product having a protection factor of at least 15 (only use after treatment). H. How Long Will The Treatments Last? May take from six to eight weeks before lesions disappear. Maintenance treatments are usually needed to keep the disease under control. I. What Are The Problems Associated With Pregnancy Or Breast Feeding? 1. Birth control methods should be employed since the effects of PUVA therapy on the unborn child are not known. If you become pregnant, inform your doctor so that he can determine whether it is necessary for you to temporarily stop therapy. 2. Since it is not known whether Oxsoralen-Ultra passes into mother’s milk, it is safer not to breast feed while taking this drug. J. What Are The Risks of PUVA Therapy? 1. Premature skin aging may result from prolonged PUVA therapy, especially with those individuals who tan poorly. This problem is similar to excessive exposure to sunlight. 2. There is an increased risk of developing both melanoma and non-melanoma skin cancer. This risk is greater for individuals who fall into the following categories: a) fair skin that burns rather than tans b) have had prior treatment with x-rays, grenz rays, or arsenic c) have had coal tar and U ltra V iolet B (UVB) treatment. Even though your doctor will be examining you, you should routinely and completely examine yourself for small growths on your skin or skin sores that will not heal. Immediately report such observations to your doctor. 3. Since studies have shown that animals with unprotected eyes have developed cataracts after PUVA therapy, you should have your eyes examined by an ophthalmologist before starting PUVA therapy, after the first year of therapy and every two years thereafter. K. What Are The Possible Side Effects? 1. The most common side effects of PUVA therapy are nausea, itching, and redness of the skin. The use of lowfat milk or food when ingesting the drug may prevent the nausea. 2. Tenderness or blistering of the skin may occur, but these symptoms can be helped by the use of skin products recommended by your doctor or pharmacist. 3. Less frequent side effects include depression, dizziness, headache, swelling, rash or leg cramps. Important: Contact your doctor if any side effect continues to bother you after 24-48 hours. L. What Else Should The Patient Know? 1. Remember to take Oxsoralen-Ultra as directed by your doctor. If you forget to take the drug before your scheduled treatment, be sure to call your doctor to determine what he wishes you to do. 2. Remember that the drug has been prescribed specifically for you and your diagnosed condition. Do not use the drug for any other conditions nor give the drug to others even if they have similar symptoms. 3. If you think that you or anyone else has accidentally taken an overdose, stay out of the sunlight and immediately contact your poison control center, doctor, pharmacist, or nearest hospital emergency room. 4. ALWAYS KEEP THIS DRUG AND ALL OTHER DRUGS OUT OF THE REACH OF CHILDREN. 5. Store at 25°C (77°F); excursions permitted to 15°C-30°C (59°F-86°F).

Manufactured for: Valeant Pharmaceuticals North America LLC Bridgewater, NJ 08807 USA

By: Heritage Pharma Labs Inc. East Brunswick, NJ 08816 USA

Rev. 02/15 9436102 51U000000155US02

PRINCIPAL DISPLAY PANEL - 10 mg Bottle Label

NDC 0187-0650-42 Rx Only

Oxsoralen-Ultra ® (Methoxsalen Capsules, USP) 10 mg

CAUTION: This new dosage form of methoxsalen exhibits significantly greater bioavailability and earlier photosensitization onset time than previous methoxsalen dosage forms. Each patient should be evaluated by determining the minimum phototoxic dose (MPD) and phototoxic peak time after drug administration prior to onset of photochemotherapy with this dosage form.

Oxsoralen 10mg Drug Information

When ordering your prescription Oxsoralen online be sure to follow the directions put forth by your doctor. If you have complications with Oxsoralen 10mg and do not believe it is working properly be sure to notify your doctor as soon as possible. Customers are not recommended to continue to use Oxsoralen 10mg medication if you have an allergic reaction to any of the ingredients within this product. It is important to speak to you doctor before you order Oxsoralen since it may cause severe side effects in patients with certain health problems. Only administer Oxsoralen 10mg to children and dogs if it indicates so.

Be sure to verify with your doctor if Oxsoralen 10mg is right for you. Oxsoralen 10mg and many other medications may react badly when taken with other medications. Ask your doctor if any of your other medications, vitamins and supplements you are taking will interfere with this product before you buy Oxsoralen 10mg online. Also be sure not to store this medicating in a moist or hot area.

All customers must provide PharmaPassport. com with a prescription from your doctor in order to buy Oxsoralen 10mg online. You can order Oxsoralen online calmly knowing that you are receiving quality Oxsoralen from a trustworthy pharmacy. PharmaPassport. com is a CIPA certified pharmacy and we guarantee to match the price of all our medication with the lowest CIPA certified pharmacy prices.

The Oxsoralen medication you purchase is manufactured by Valeant Canada. Methoxsalen is the generic alternative to Oxsoralen.

Customers can buy Oxsoralen from PharmaPassport. com 24 hours a day and 7 days a week easily. The quick and easy shipping is reliable and will get your Oxsoralen to your house 2 to 4 weeks from the day you ordered it. As a reputable online pharmacy, PharmaPassport. com provides all their customers with the 3 part guarantee from buySAFE. Choose PharmaPassport. com when you buy Oxsoralen 10mg and all your other prescription medications.

Professional Standards and Safety

PharmaPassport has a clean, spotless patient safety record that proves our commitment to customer safety. We:

Do not provide access to controlled, habit forming substances.

Do not provide access to prescription medications without a prescription from a physician.

Do contact the doctor's office to verify each prescription before it is filled.

Do have licensed Canadian physicians that reviews every customer's medical history to identify potential complications. A new prescription for the patients' preferred brand or generic medication will be written by our doctors to prevent the potential complications.

START SAVING ON CYMBALTA

Information provided on this website is for general purposes only. It is not intended to take the place of advice from your practitioner.

All trademarks and registered trademarks appearing on this website are the property of their respective owners and pharmapassport. com is not affiliated with them in any way.

Feel free to contact our Customer Care Specialists by: Calling Us Toll-Free: 1-866-293-3904 Faxing Us Toll-Free: 1-866-732-0306 Emailing Us: info@pharmapassport. com

Copyright © 2016 PharmaPassport. com. com. All Rights Reserved.

CALL US TOLL-FREE 1-866-293-3904

FAX US TOLL-FREE 1-866-732-0306

Oxsoralen 10mg is a prescription required product. Once you complete your order, please mail a VALID PRESCRIPTION to PharmaPassport to complete your purchase of Oxsoralen 10mg.

At PharmaPassport you can buy Oxsoralen 10mg with Personal Checks, E-checks, International Money Orders, and Certified Checks. All prices quoted on PharmaPassport are in US Dollars.

Shipping

A shipping fee of $9.95 is charged per patient order within United States. Additional charges may apply for overweight packages.

Professional Standards and Safety

PharmaPassport has a clean, spotless patient safety record that proves our commitment to customer safety. We:

Do not provide access to controlled, habit forming substances.

Do not provide access to prescription medications without a prescription from a physician.

Do contact the doctor's office to verify each prescription before it is filled.

Do have licensed Canadian physicians that reviews every customer's medical history to identify potential complications. A new prescription for the patients' preferred brand or generic medication will be written by our doctors to prevent the potential complications.

START SAVING ON CYMBALTA

Information provided on this website is for general purposes only. It is not intended to take the place of advice from your practitioner.

All trademarks and registered trademarks appearing on this website are the property of their respective owners and pharmapassport. com is not affiliated with them in any way.

Feel free to contact our Customer Care Specialists by: Calling Us Toll-Free: 1-866-293-3904 Faxing Us Toll-Free: 1-866-732-0306 Emailing Us: info@pharmapassport. com

Copyright © 2016 PharmaPassport. com. com. All Rights Reserved.

CALL US TOLL-FREE 1-866-293-3904

FAX US TOLL-FREE 1-866-732-0306

Concour - definition of concour by the free dictionary, concorz

recruitment

recruitment

recruit

1. a person who has (just) joined the army, air force etc . rekruut ???????? новобранец recruta branec der/die Rekrut(in) rekrut ???????????? recluta nekrut ?????? ????? ???? alokas recrue ????? ?????? novak, regrut ujonc prajurit baru nyli?i recluta ?? ?? naujokas jauniesaucamais rekrut rekruut rekrutt rekrut ?????? ??????? ?????????? ????? ???? ????? ??? ?? ?????? ??? ????? ??? ????? ??? ?????? ??? ??? recruta recrut новобранец odvedenec novinec regrut rekryt ???????? acemi asker ?? призовник, новобранець ??? ????? ??? ????? linh m?i ??

2. a person who has (just) joined a society, group etc . Our party needs new recruits before the next election. nuweling ??????? ?????? нов член novo membro novy clen der Neuling nyt medlem ??? ????? nuevo miembro uustulnuk ??? ???? uusi jasen recrue ????? ???? ?? ?? ????? ?? ??? ????? novi clan, novajlija uj tag anggota baru nyr me?limur socio ??? ?? ?? naujas narys jauns biedrs; jauninais ahli nieuw lid ny tilhenger. nytt medlem swiezy nabytek ??? ???? novo membro nou membru новый член novy clen, novacik novinec novi clan nykomling, ny medlem ?????????? yeni uye ??? новий член ??? ????? ?? ??? ??? thanh vien m?i ???

to cause to join the army, a society etc . We must recruit more troops; Can't you recruit more members to the music society? werf ???????? набирам recrutar sebrat, ziskat einziehen rekruttere ?????????? reclutar ; conseguir varbama ????? ?????? ?? ???? ?????? ?? ???? varvata recruter ???????? ??? ????? ???? novaciti, regrutirati toboroz merekrut fa nyja me?limi arruolare. reclutare ???? ??(??)?? telkti, verbuoti vervet; pieaicinat mengambil ahli aanwerven rekruttere. verve (z)werbowac ????? recrutar a re­cruta набирать pozbierat; ziskat novaciti regrutovati rekrytera ????????????? yazmak. almak ??,?? вербувати ??? ????? ???? tuy?n m? ??,??

werwing ??????? набиране recrutamento odvod, nabor die Rekrutierung rekruttering ???????????? reclutamiento varbamine ???????? ????? ???? varvays recrutement ???? ????? novacenje, regrutiranje sorozas, toborzas perekrutan sofnun/skraning nyrra me?lima arruolamento. reclutamento ?? ?? telkimas, verbavimas vervesana; pieaicinasana pengambilan ahli aanwerving rekruttering. verving rekrutacja ????? recrutamento recrutare набор odvadzanie; ziskavanie novacenje regrutacija rekryt-ering ???????????? uye kaydetme ??,?? набір новобранців ??????? ?? ??? ????? s? tuy?n m? ??

recruitment

Link to this page:

References in periodicals archive ?

He has exhibited his works at classic car shows and conventions such as the Pebble Beach Concour d' Elegance, the Cavallino Classic in Palm Beach, the Meadow Brook Concour d' Elegance, as well as in the Austin Art Museum in Texas.

Linear T5HO wide-distribution bands of light follow a radial procession in t he concour ses to prov ide the ambient light.

We were second in the concour de elegance class and then won the Equitation class and won the award for best turned out.

Flucofast, kaps, flucofast

Flucofast, kaps. twarde, 100 mg

myHealthbox™ is a leading provider of health information services to consumers and healthcare professionals.

myHealthbox™ provides a platform to access official Patient Information Leaflets (PIL) and Summary of Product Characteristics (SPC) documents on healthcare products including: human, animal and plants medications; drugs; herbal, homoeopathic and natural remedies; prescription and over-the-counter medicines; beauty products and cosmetics; supplements and medical devices.

Home - semper fi fund, sefur

Get Assistance

Donate Now

Get Involved

Dirt Rag Magazine | by Clayton Wangbichler | September 13, 2016 2:10pm | Link to Article Semper Fidelis, meaning “always faithful.” This is the motto of the U. S. Marine Corps. To many, presence of the motto in our lives is likely limited to the stickers proudly and neatly displayed on the vehicles of our nation’s veterans. To a Marine, it’s…

I had a friend say to me the other day, “Can you believe that kids starting high school this week are of an age that most of them weren’t even born yet when 9/11 happened?” The comment made me stop and think about the passage of time. It’s been 15 years since we all woke up to…

Announcing the inaugural Rob Riggle InVETational Golf Classic; celebrating two things Rob Riggle really loves — veterans and golf — all in support of Semper Fi Fund, an organization which is doing a tremendous amount of good for veterans and their families. “I couldn’t be more pleased to have this extraordinary organization benefit from my first…

Join us September 7th-18th, 2016 as we cheer on six of our service members who are participating in the 2016 Summer Paralympics! This major international multi-sport event for athletes with disabilities is governed by the International Paralympic Committee, and will be held in Rio de Janeiro, Brazil. Opening ceremonies will take place on the evening of September 7th. The games will follow with 23 sports and more than…

CFC 2016! Your CFC donation will have a real IMPACT in the lives of wounded, critically ill and injured members of all branches of the U. S. Armed Forces and their families if you designate the Semper Fi Fund this year. Important Semper Fi Fund information to consider: – The Semper Fi Fund has been awarded the highest ratings from watchdog groups:…

Story and photography by MATT BROCKMAN The Jinx McCain Horsemanship Program ignites a sense of purpose in wounded warriors. JOHN MAYER REMEMBERS THE FIRST TIME HE LOST A FELLOW SOLDIER IN COMBAT. “He was 19 years old and pretty much bled to death in my arms,” recalls Mayer, a 33-year-old U. S. Marine Corps officer who…

SEPT. 21, 2015 (NEW YORK, NY) – Since January 2012, the Semper Fi Fund has provided nearly $2.5 million to the Stephen Siller Tunnel to Towers Foundation. That tradition of giving, and of honoring the sacrifices made by first responders in the fight against terrorism, will continue September 25 in New York City at the…

Washington, DC (September 19, 2016) The Semper Fi Fund and The Home Depot Foundation have announced an expanded partnership that will mean more assistance to post-9/11 wounded, critically ill and injured members of all branches of the U. S. Armed Forces and their families. The Home Depot Foundation will be providing $2.2 million to assist the…

Bike Radar | By Josh Patterson | September 14, 2016 6:42am GMT | Link to Article $15 from each Stars and Stripes WTB Volt donated to veteran’s foundation WTB in conjunction with the Semper Fi Fund has released a special edition of its popular Volt saddle emblazoned with the stars and stripes. A portion of the proceeds from the sale…

Dirt Rag Magazine | by Clayton Wangbichler | September 13, 2016 2:10pm | Link to Article Semper Fidelis, meaning “always faithful.” This is the motto of the U. S. Marine Corps. To many, presence of the motto in our lives is likely limited to the stickers proudly and neatly displayed on the vehicles of our nation’s veterans. To a Marine, it’s…

I had a friend say to me the other day, “Can you believe that kids starting high school this week are of an age that most of them weren’t even born yet when 9/11 happened?” The comment made me stop and think about the passage of time. It’s been 15 years since we all woke up to…

LOS ANGELES, CA (PRWEB) | THURSDAY, SEPTEMBER 08, 2016 | Link to Press Release We Are The Mighty (WATM), the military’s media and entertainment brand, and Marine Corps veteran, actor and comedian Rob Riggle presents the inaugural Rob Riggle InVETational Golf Classic. The veteran-celebrity golf tournament will raise money and awareness for the Semper Fi Fund. We…

Posted on September 12, 2016 At 7 a. m. on September 11, 2001, Dan Lasko was in Harrisburg, Pennsylvania, being sworn in as a Marine. Less than two hours later, American Airlines Flight 11 crashed into the North Tower of the World Trade Center, followed minutes later by United Airlines Flight 175 crashing into the South…

Posted September 6, 2016 This week, retired Sergeant Mike Wishnia heads to Rio where he’ll be going for the Gold at the Paralympic Games–he is the two-time national champion for the F57 shotput and currently ranked second in the world. Prior to last year, the Olympics were never on his radar–in fact, up until two…

Posted on June 29, 2016 Now 42 years old, Jake enlisted in June 1992. He always knew he wanted to be in the Navy. His father, his uncle and both grandparents all served, but Jake decided he wanted something else. I didn’t want to be a sailor on a ship, I wanted something a little more…

Posted on June 17, 2016 On August 9, 2014, Staff Sergeant Brandon Dodson lost both his legs to an improvised explosive device blast in Shah Pusta, Afghanistan. He was on his fifth deployment. About 19 months later, in mid-March 2016, Brandon completed a Team Semper Fi surf camp. It was his fifth time surfing since…

Posted on June 17, 2016 Staff Sergeant Brandon Dodson lost both his legs to an improvised explosive device blast in Afghanistan in 2014. He was on his fifth deployment, and you can read his full story over here. At the time Brandon was injured, his son was only 18 months old — which gives him…

Posted on May 7, 2016 Captain, USMC (Retired) Sarah Bettencourt has quite a resume. She graduated from the U. S. Naval Academy in 2005. She earned a Master of Science degree in mechanical engineering from Stanford University—while serving with the 23rd Marine Regiment. She founded the San Diego Ducks Sled Hockey club, sponsored by the National…

Here is your chance to learn how to pack equipment into the mountains on horses and mules in this dedicated packing clinic in the magnificent San Juan Mountains near Montrose, CO. Top guide Larry Franks will provide detailed instructions, mules and horses, and necessary equipment to teach our riders the skills of this timeless outdoorsman…

This is a 3-day golf clinic located at The Promontory Golf Club in Park City, UT. We will be working with the pros from their golf club. This is the first year we have hosted an event at this location. We have been running golf clinics like this for 3 years. We have 14 total Service…

Auto Specialist Warehouse is celebrating their 23rd year in business by hosting a private Summer Bash for their vendors and business partners. They are celebrating with great food, entertainment and raffle to benefit the Semper Fi Fund. * This is a private event.

Branford, CT – Every Wednesday is Charity Night at the Stony Creek Brewery! For every Stony Creek beer that is purchased, you will receive a wooden token. The token represents $1 that Stony Creek Brewery will donate to the charity of your choice! Just place it in one of three boxes: American Red Cross, Branford Cares,…

Please come join us and hear about all the exciting ways you can volunteer to help our wounded, critically ill and injured service members and their families. Please email selena. obrien@semperfifund. org to be added to the event email list. Click HERE download the flyer information.

Shop To Support The Fund

What we wear is an expression of ourselves. In wearing a Tyawear scarf, we can dress in something we believe in. We tie a scarf, pledging to spread awareness about charitable organizations and their missions. Each Tyawear scarf holds the message and intent of one of our charitable partnerships. The design of each scarf includes imagery and motifs…

Shop To Support The Fund

“I Am Alive” tells a story of the battle our soldiers face when they return from deployment, left to transition into civilian life again. It is a struggle for brave men and women. Purchase the record today and Crack in the Shell will donate 50% of the revenue to Semper Fi Fund. Visit our Website…

Shop To Support The Fund

“Ride The Thunder” is the true heroic story of a friendship between American Marine Legend, John Ripley and Vietnamese Hero, Marine Le Ba Binh. The storyline follows their fight together against the communists during the Vietnam War and then the ensuing aftermath of the fall of Vietnam as Ripley goes home to a divided America…

Shop To Support The Fund

Alone and Unafraid is a clothing line featuring Street, Lounge and Fitness clothing. Alone and Unafraid is disabled veteran owned and operated and all products are made in America. 5% of all sales will be donated to Semper Fi Fund. Visit our website to shop. http://www. aloneandunafraid. com/

Shop To Support The Fund

Burnt Wood American Flags Custom-made American flags by American Patriot’s Story. These beautiful wooden flags are handmade by a combat-wounded Marine who served in the Iraq War. 10% of the proceeds will benefit the Semper Fi Fund. To learn more, please visit The American Patriots Story on Facebook or visit The American Patriots Story shop…

Shop To Support The Fund

AKeyMark is a web-based legal services platform. AKeyMark reinvents the attorney-client relationship for trademark registration. The platform bridges the gap between cheap, online self-filing services and expensive attorneys by cost effectively combining the ease and efficiency with the representation and counsel of an expert trademark attorney. As proud Semper Fi Fund supporters, AKeyMark has pledged…

Beafemic (mefenamic acid) drug & pharmaceuticals, beafemic

Medication: Beafemic

Beafemic - A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.

Indication: For the treatment of rheumatoid arthritis, osteoarthritis, dysmenorrhea, and mild to moderate pain, inflammation, and fever.

Beafemic, an anthranilic acid derivative, is a member of the fenamate group of nonsteroidal anti-inflammatory drugs (NSAIDs). It exhibits anti-inflammatory, analgesic, and antipyretic activities. Similar to other NSAIDs, Beafemic inhibits prostaglandin synthetase.

Pharmaceutical active ingredients containing related brand and generic drugs, medications or other health care products:

Beafemic available forms, composition, doses:

Capsules; Oral; Mefenamic Acid 250 mg

Suspension; Oral; Mefenamic Acid 50 mg / 5 ml

Beafemic destination | category:

Human:

Nonsteroidal anti-inflammatory drugs (NSAIDs)

Indications and usages, anatomical therapeutic chemical and diseases classification codes:

Pharmaceutical companies, researchers, developers, manufacturers, distributors and suppliers:

Camidexon, camidexon

Decadron is used to treat conditions such as arthritis, blood/hormone/immune system disorders, allergic reactions, certain skin and eye conditions, breathing problems, certain bowel disorders. Also it is used in the treatment of cancers of the white blood cells (leukemias), and lymph gland cancers (lymphomas).

Availability: In Stock (34 packs)

Other names of Decadron:

Product Description Common use Decadron is used to treat conditions such as arthritis, blood/hormone/immune system disorders, allergic reactions, certain skin and eye conditions, breathing problems, certain bowel disorders. Also it is used in the treatment of cancers of the white blood cells (leukemias), and lymph gland cancers (lymphomas). Finally, Decadron is used as replacement therapy in patients whose adrenal glands are unable to produce sufficient amounts of corticosteroids.

Dosage and direction Take this medication by mouth as directed by your doctor. The initial oral dose is 0.75 to 9 mg daily depending on the disease. The initial dose should be adjusted according to the response to therapy. Take with food or milk to prevent stomach upset. Take this medication by mouth with food or a full glass of water or milk unless your doctor directs you otherwise. If you take this medication once daily, take it in the morning before 9 AM. Use this medication regularly in order to get the most benefit from it. Take it at the same time(s) each day. It is important to continue taking this medication even if you feel well. Follow the dosing schedule carefully, and take this medication exactly as prescribed. Do not stop taking this medication without consulting your doctor. Inform your doctor if your condition does not improve or worsens.

Precautions Do not get immunizations, vaccinations, or skin tests unless specifically directed by your doctor. Before taking Decadron, tell your doctor or pharmacist if you have any allergies, your medical history: active fungal infections, kidney or liver disease, mental/mood conditions, low blood minerals, thyroid disease, stomach/intestinal problems, high blood pressure, heart problems, diabetes, eye diseases, brittle bones, history of blood clots. If you have been taking this medication for a long time, your body may not make enough natural hormones while you are under physical stress. Your dose may need to be adjusted. If you have stopped taking this drug within the past 12 months, you may need to start taking it again if your body is under physical stress. Before having surgery, tell your doctor or dentist that you are using this medication or have taken it within the last 12 months. If you have a history of ulcers or take large doses of aspirin or other arthritis medication. Limit alcoholic beverages while taking this medication to decrease the risk of stomach/intestinal bleeding. If you have diabetes, this drug may make it harder to control your blood sugar levels. Monitor your blood sugar levels regularly and inform your doctor of the results. During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor. This drug may pass into breast milk and could have undesirable effects on a nursing infant. Therefore, breast-feeding is not recommended while using this medication. Avoid contact with people who have recently received oral polio vaccine or flu vaccine inhaled through the nose, chickenpox or measles unless you have previously had these diseases (in childhood). If you are exposed to one of these infections and you have not previously had it, seek immediate medical attention.

Contraindications Do NOT use Decadron if you are allergic to any ingredient in Decadron, you have a systemic fungal infection, you are taking mifepristone. Contact your doctor or health care provider immediately if any of these apply to you.

Possible side effects

Side effects of Decadron depend on the dose, the duration and the frequency of administration. Short courses of dexamethasone usually are well tolerated with few and mild side effects. Long term, high dose dexamethasone usually will produce predictable and potentially serious side effects. Whenever possible, the lowest effective dose of dexamethasone should be used for the shortest possible length of time to minimize side effects. Alternate day dosing also can help reduce side effects. Side effects include fluid retention, weight gain, high blood pressure, loss of potassium, headache, muscle weakness, puffiness, and hair growth on the face, thinning and easy bruising of skin, glaucoma, cataracts, peptic ulceration, worsening of diabetes, irregular menses, growth retardation in children, convulsions, stomach upset, headache, dizziness, menstrual changes, trouble sleeping, increased appetite, or weight gain may occur, depression, euphoria, insomnia, mood swings, personality changes, and even psychotic behavior. A very serious allergic reaction to this drug is rare. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.

Drug interactions Drugs such as phenobarbital, ephedrine, phenytoin (Dilantin), and rifampin (Rifadin, Rimactane) may increase the breakdown of corticosteroids by the liver. As a result it may be lower blood levels and reduced effects. Therefore, the dose of corticosteroid may need to be increased if treatment with any of these agents is begun.

Missed dose If you are taking this medication daily and on a regular schedule, and you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose and resume your usual dosing schedule. Do not double the dose to catch up.

Overdose Seek emergency medical attention if you think you have used too much of this medicine.

Storage Decadron should be stored at 68-77 F (20-25 C) and not frozen

Disclaimer We provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information on the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.

Decadron is used to treat conditions such as arthritis, blood/hormone/immune system disorders, allergic reactions, certain skin and eye conditions, breathing problems, certain bowel disorders. Also it is used in the treatment of cancers of the white blood cells (leukemias), and lymph gland cancers (lymphomas).

Availability: In Stock (34 packs)

Other names of Decadron:

Product Description Common use Decadron is used to treat conditions such as arthritis, blood/hormone/immune system disorders, allergic reactions, certain skin and eye conditions, breathing problems, certain bowel disorders. Also it is used in the treatment of cancers of the white blood cells (leukemias), and lymph gland cancers (lymphomas). Finally, Decadron is used as replacement therapy in patients whose adrenal glands are unable to produce sufficient amounts of corticosteroids.

Dosage and direction Take this medication by mouth as directed by your doctor. The initial oral dose is 0.75 to 9 mg daily depending on the disease. The initial dose should be adjusted according to the response to therapy. Take with food or milk to prevent stomach upset. Take this medication by mouth with food or a full glass of water or milk unless your doctor directs you otherwise. If you take this medication once daily, take it in the morning before 9 AM. Use this medication regularly in order to get the most benefit from it. Take it at the same time(s) each day. It is important to continue taking this medication even if you feel well. Follow the dosing schedule carefully, and take this medication exactly as prescribed. Do not stop taking this medication without consulting your doctor. Inform your doctor if your condition does not improve or worsens.

Precautions Do not get immunizations, vaccinations, or skin tests unless specifically directed by your doctor. Before taking Decadron, tell your doctor or pharmacist if you have any allergies, your medical history: active fungal infections, kidney or liver disease, mental/mood conditions, low blood minerals, thyroid disease, stomach/intestinal problems, high blood pressure, heart problems, diabetes, eye diseases, brittle bones, history of blood clots. If you have been taking this medication for a long time, your body may not make enough natural hormones while you are under physical stress. Your dose may need to be adjusted. If you have stopped taking this drug within the past 12 months, you may need to start taking it again if your body is under physical stress. Before having surgery, tell your doctor or dentist that you are using this medication or have taken it within the last 12 months. If you have a history of ulcers or take large doses of aspirin or other arthritis medication. Limit alcoholic beverages while taking this medication to decrease the risk of stomach/intestinal bleeding. If you have diabetes, this drug may make it harder to control your blood sugar levels. Monitor your blood sugar levels regularly and inform your doctor of the results. During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor. This drug may pass into breast milk and could have undesirable effects on a nursing infant. Therefore, breast-feeding is not recommended while using this medication. Avoid contact with people who have recently received oral polio vaccine or flu vaccine inhaled through the nose, chickenpox or measles unless you have previously had these diseases (in childhood). If you are exposed to one of these infections and you have not previously had it, seek immediate medical attention.

Contraindications Do NOT use Decadron if you are allergic to any ingredient in Decadron, you have a systemic fungal infection, you are taking mifepristone. Contact your doctor or health care provider immediately if any of these apply to you.

Possible side effects

Side effects of Decadron depend on the dose, the duration and the frequency of administration. Short courses of dexamethasone usually are well tolerated with few and mild side effects. Long term, high dose dexamethasone usually will produce predictable and potentially serious side effects. Whenever possible, the lowest effective dose of dexamethasone should be used for the shortest possible length of time to minimize side effects. Alternate day dosing also can help reduce side effects. Side effects include fluid retention, weight gain, high blood pressure, loss of potassium, headache, muscle weakness, puffiness, and hair growth on the face, thinning and easy bruising of skin, glaucoma, cataracts, peptic ulceration, worsening of diabetes, irregular menses, growth retardation in children, convulsions, stomach upset, headache, dizziness, menstrual changes, trouble sleeping, increased appetite, or weight gain may occur, depression, euphoria, insomnia, mood swings, personality changes, and even psychotic behavior. A very serious allergic reaction to this drug is rare. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.

Drug interactions Drugs such as phenobarbital, ephedrine, phenytoin (Dilantin), and rifampin (Rifadin, Rimactane) may increase the breakdown of corticosteroids by the liver. As a result it may be lower blood levels and reduced effects. Therefore, the dose of corticosteroid may need to be increased if treatment with any of these agents is begun.

Missed dose If you are taking this medication daily and on a regular schedule, and you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose and resume your usual dosing schedule. Do not double the dose to catch up.

Overdose Seek emergency medical attention if you think you have used too much of this medicine.

Storage Decadron should be stored at 68-77 F (20-25 C) and not frozen

Disclaimer We provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information on the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.

Fenotral, fenotral

Benadryl is an antihistamine. Diphenhydramine blocks the effects of the naturally occurring chemical histamine in the body. It is used to treat sneezing; runny nose; itching, watery eyes; hives; rashes; and other symptoms of allergies and the common cold.

Availability: In Stock (14 packs)

Benadryl is used for preventing or treating symptoms of hay fever and other upper respiratory allergies or the common cold, such as runny nose, sneezing, itching of the nose and throat, and itchy, watery eyes, and relieving cough.

Do not take Benadryl if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), phenelzine (Nardil), or tranylcypromine (Parnate) in the last 14 days. A very dangerous drug interaction could occur, leading to serious side effects.

Before taking Benadryl, tell your doctor if you have:

glaucoma or increased pressure in the eye;

a stomach ulcer;

an enlarged prostate, bladder problems or difficulty urinating;

an overactive thyroid (hyperthyroidism);

hypertension or any type of heart problems; or

asthma.

You may not be able to take Benadryl, or you may require a lower dose or special monitoring during treatment if you have any of the conditions listed above.

Take Benadryl exactly as directed on the package or as directed by your doctor. If you do not understand these directions, ask your pharmacist, nurse, or doctor to explain them to you.

Take each dose with a full glass of water.

Benadryl can be taken with or without food.

For motion sickness, a dose is usually taken 30 minutes before motion, then with meals and at bedtime for the duration of exposure.

As a sleep aid, Benadryl should be taken approximately 30 minutes before bedtime.

To ensure that you get a correct dose, measure the liquid forms of Benadryl with a special dose-measuring spoon or cup, not with a regular tablespoon. If you do not have a dose-measuring device, ask your pharmacist where you can get one.

Never take more of Benadryl than is prescribed for you. The maximum amount of diphenhydramine that you should take in any 24-hour period is 300 mg.

Take the missed dose as soon as you remember. However, if it is almost time for the next dose, skip the missed dose and take only the next regularly scheduled dose. Do not take a double dose of Benadryl unless otherwise directed by your doctor.

Do NOT use more than directed.

Adults and children 12 years of age and over - 25 mg to 50 mg (1 to 2 capsules).

Children 6 to under 12 years of age - 12.5 mg ** to 25 mg (1 capsule).

Children under 6 years of age - consult a doctor.

Store Benadryl at room temperature between 68 and 77 degrees F (20 and 25 degrees C) in a tightly closed container. Brief periods at temperatures of 59 to 86 degrees F (15 to 30 degrees C) are permitted. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Benadryl out of the reach of children and away from pets.

Before taking diphenhydramine, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: breathing problems (e. g. asthma, emphysema), glaucoma, heart problems, high blood pressure, liver disease, mental/mood changes, seizures, stomach problems (e. g. ulcers, obstruction), an overactive thyroid gland, difficulty urinating (e. g. due to an enlarged prostate gland).

Benadryl is in the FDA pregnancy category B. This means that it is not expected to be harmful to an unborn baby. Do not take Benadryl without first talking to your doctor if you are pregnant. Infants are especially sensitive to the effects of antihistamines, and side effects could occur in a breast-feeding baby. Do not take Benadryl without first talking to your doctor if you are nursing a baby.

If you are over 60 years of age, you may be more likely to experience side effects from Benadryl. You may require a lower dose of Benadryl.

Stop taking Benadryl and seek emergency medical attention if you experience an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives).

Other, less serious side effects may be more likely to occur. Continue to take Benadryl and talk to your doctor if you experience:

sleepiness, fatigue, or dizziness;

headache;

dry mouth; or

difficulty urinating or an enlarged prostate.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

When using this product:

marked drowsiness may occur

avoid alcoholic drinks

alcohol, sedatives, and tranquilizers may increase drowsiness

excitability may occur, especially in children

be careful when driving a motor vehicle or operating machinery

Benadryl is an antihistamine. Diphenhydramine blocks the effects of the naturally occurring chemical histamine in the body. It is used to treat sneezing; runny nose; itching, watery eyes; hives; rashes; and other symptoms of allergies and the common cold.

Availability: In Stock (14 packs)

Analogs of: Benadryl

Other names of Benadryl:

Benadryl is used for preventing or treating symptoms of hay fever and other upper respiratory allergies or the common cold, such as runny nose, sneezing, itching of the nose and throat, and itchy, watery eyes, and relieving cough.

Do not take Benadryl if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), phenelzine (Nardil), or tranylcypromine (Parnate) in the last 14 days. A very dangerous drug interaction could occur, leading to serious side effects.

Before taking Benadryl, tell your doctor if you have:

glaucoma or increased pressure in the eye;

a stomach ulcer;

an enlarged prostate, bladder problems or difficulty urinating;

an overactive thyroid (hyperthyroidism);

hypertension or any type of heart problems; or

asthma.

You may not be able to take Benadryl, or you may require a lower dose or special monitoring during treatment if you have any of the conditions listed above.

Take Benadryl exactly as directed on the package or as directed by your doctor. If you do not understand these directions, ask your pharmacist, nurse, or doctor to explain them to you.

Take each dose with a full glass of water.

Benadryl can be taken with or without food.

For motion sickness, a dose is usually taken 30 minutes before motion, then with meals and at bedtime for the duration of exposure.

As a sleep aid, Benadryl should be taken approximately 30 minutes before bedtime.

To ensure that you get a correct dose, measure the liquid forms of Benadryl with a special dose-measuring spoon or cup, not with a regular tablespoon. If you do not have a dose-measuring device, ask your pharmacist where you can get one.

Never take more of Benadryl than is prescribed for you. The maximum amount of diphenhydramine that you should take in any 24-hour period is 300 mg.

Take the missed dose as soon as you remember. However, if it is almost time for the next dose, skip the missed dose and take only the next regularly scheduled dose. Do not take a double dose of Benadryl unless otherwise directed by your doctor.

Do NOT use more than directed.

Adults and children 12 years of age and over - 25 mg to 50 mg (1 to 2 capsules).

Children 6 to under 12 years of age - 12.5 mg ** to 25 mg (1 capsule).

Children under 6 years of age - consult a doctor.

Store Benadryl at room temperature between 68 and 77 degrees F (20 and 25 degrees C) in a tightly closed container. Brief periods at temperatures of 59 to 86 degrees F (15 to 30 degrees C) are permitted. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Benadryl out of the reach of children and away from pets.

Before taking diphenhydramine, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: breathing problems (e. g. asthma, emphysema), glaucoma, heart problems, high blood pressure, liver disease, mental/mood changes, seizures, stomach problems (e. g. ulcers, obstruction), an overactive thyroid gland, difficulty urinating (e. g. due to an enlarged prostate gland).

Benadryl is in the FDA pregnancy category B. This means that it is not expected to be harmful to an unborn baby. Do not take Benadryl without first talking to your doctor if you are pregnant. Infants are especially sensitive to the effects of antihistamines, and side effects could occur in a breast-feeding baby. Do not take Benadryl without first talking to your doctor if you are nursing a baby.

If you are over 60 years of age, you may be more likely to experience side effects from Benadryl. You may require a lower dose of Benadryl.

Stop taking Benadryl and seek emergency medical attention if you experience an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives).

Other, less serious side effects may be more likely to occur. Continue to take Benadryl and talk to your doctor if you experience:

sleepiness, fatigue, or dizziness;

headache;

dry mouth; or

difficulty urinating or an enlarged prostate.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

When using this product:

marked drowsiness may occur

avoid alcoholic drinks

alcohol, sedatives, and tranquilizers may increase drowsiness

excitability may occur, especially in children

be careful when driving a motor vehicle or operating machinery

Why register with MediGuard?

We are a free monitoring service designed for patients like you who want to be in the driver seat of your medical treatment. We have a community of more than 2.6 million members and offer the services below.

Medication Information Personalized Risk Rating Easy to understand overview Serious Side Effects Printable Medication List

Information you can understand Overview on Safety Alerts & Recalls Overview of Medications & Conditions

Community of patients Members’ Feedback Members Treatment Satisfaction

Health condition information Easy to understand overview Commonly Used Medications

Safety checks Safety Alerts & Recalls Drug - Drug Interaction Drug - Condition Interaction

Research participation Option to participate in medical surveys & studies*

Fenotral

What is your Risk Rating for this medicine?

The risk of serious side effects for taking this medicine can be different if you take other medicines or if you suffer from a condition. Get your Risk Rating by creating a profile in a few steps.

Benefits:

We monitor your health and alert you to any safety updates and recalls.

You get to talk directly to other members about their experience.

You can create profiles for you and your loved ones.

Create my Profile Learn more about Risk Ratings

Other Names

Expand to see all

Share your story! Tell us how MediGuard has helped you or someone you love. Download the MediGuard Mobile App to manage your prescription and over-the-counter medications, for free. Taking multiple medications puts you at risk for possible drug-drug interactions Monitor the medical treatment of you and your loved ones.

DISCLAIMER: MediGuard is not intended to be a substitute for professional medical advice. MediGuard cannot and does not take into consideration every possible interaction or account for individual responses to medicine. Different individuals may respond to medication in different ways. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Always seek the advice of a qualified health provider with any questions you may have before making any changes to your treatment. The use of the MediGuard site and its content is at your own risk. The MediGuard site and the information contained in it is intended for users in the United States and information in other countries may be different.

© Quintiles 2016

Depakote drug uses, dosage - side effects, depa 125mg

Depakote

Depakote (divalproex sodium) affects chemicals in the body that may be involved in causing seizures.

Depakote is used to treat various types of seizure disorders. It is sometimes used together with other seizure medications.

Depakote is also used to treat manic episodes related to bipolar disorder (manic depression), and to prevent migraine headaches.

Depakote may also be used for purposes not listed in this medication guide.

Important information

Do not use Depakote to prevent migraine headaches if you are pregnant.

If you take Depakote for seizures or manic episodes: Do not start or stop taking the medicine during pregnancy without your doctor's advice. Divalproex sodium may cause harm to an unborn baby, but having a seizure during pregnancy could harm both the mother and the baby.

You should not use Depakote if you have liver disease, a urea cycle disorder, or a genetic disorder such as Alpers' disease or Alpers-Huttenlocher syndrome (especially in a child younger than 2 years old).

Depakote can cause liver failure that may be fatal, especially in children under age 2 and in people with liver problems caused by a genetic mitochondrial (MYE-toe-KON-dree-al) disorder.

Call your doctor at once if the person taking this medicine has early signs of liver or pancreas problems, such as: loss of appetite, upper stomach pain (that may spread to your back), ongoing nausea or vomiting, dark urine, swelling in the face, or jaundice (yellowing of the skin or eyes).

Before taking this medicine

You should not use Depakote if you are allergic to divalproex sodium, or if you have:

a urea cycle disorder; or

a genetic mitochondrial (MYE-toe-KON-dree-al) disorder such as Alpers' disease or Alpers-Huttenlocher syndrome, especially in a child younger than 2 years old.

Depakote can cause liver failure that may be fatal, especially in children under age 2 and in people with liver problems caused by a genetic mitochondrial disorder.

To make sure this medicine is safe for you, tell your doctor if you have:

liver problems caused by a genetic mitochondrial disorder;

a history of depression, mental illness, or suicidal thoughts or actions;

a family history of a urea cycle disorder or infant deaths with unknown cause; or

HIV or CMV (cytomegalovirus) infection.

Some young people have thoughts about suicide when first taking Depakote. Your doctor will need to check your progress at regular visits while you are using this medicine. Your family or other caregivers should also be alert to changes in your mood or symptoms.

Do not use Depakote to prevent migraine headaches if you are pregnant.

If you take Depakote for seizures or manic episodes: This medicine can harm an unborn baby or cause birth defects, and may affect cognitive ability (reasoning, intelligence, problem-solving) later in the child's life. However, having a seizure during pregnancy could harm both the mother and the baby. Do not start or stop taking the medicine during pregnancy without your doctor's advice.

Use effective birth control while using Depakote, and tell your doctor right away if you become pregnant.

Seizure control is very important during pregnancy. The benefit of preventing seizures may outweigh any risks posed by taking Depakote. There may be other seizure medications that can be more safely used during pregnancy. Follow your doctor's instructions about taking this medicine while you are pregnant.

Divalproex sodium can pass into breast milk and may harm a nursing baby. Tell your doctor if you are breast-feeding a baby.

How should I take Depakote?

Take Depakote exactly as prescribed by your doctor. Follow all directions on your prescription label. Your doctor may occasionally change your dose to make sure you get the best results. Do not take this medicine in larger or smaller amounts or for longer than recommended.

Drink plenty of water while you are taking this medication. Your dose may need to be changed if you do not get enough fluids each day.

You may open the Depakote sprinkle capsule and sprinkle the medicine into a spoonful of pudding or applesauce to make swallowing easier. Swallow this mixture right away.

Do not crush, chew, break, or open a delayed-release or extended-release tablet or capsule. Swallow it whole.

While using Depakote, you may need frequent blood tests.

Wear a medical alert tag or carry an ID card stating that you take Depakote. Any doctor, dentist, or emergency medical care provider who treats you should know that you are taking a seizure medication.

Do not stop using Depakote suddenly, even if you feel fine. Stopping suddenly may cause a serious, life-threatening type of seizure. Follow your doctor's instructions about tapering your dose.

Store at room temperature away from moisture and heat.

What happens if I miss a dose?

Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid?

Drinking alcohol may increase certain side effects of Depakote.

Depakote may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert.

Avoid exposure to sunlight or tanning beds. Divalproex sodium can make you sunburn more easily. Wear protective clothing and use sunscreen (SPF 30 or higher) when you are outdoors.

Depakote side effects

Get emergency medical help if you have any of these signs of an allergic reaction: to Depakote hives; fever, swollen glands, mouth sores, difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if the person taking this medicine has early signs of liver or pancreas problems, such as: loss of appetite, upper stomach pain (that may spread to your back), ongoing nausea or vomiting, dark urine, swelling in the face, or jaundice (yellowing of the skin or eyes).

Report any new or worsening symptoms to your doctor, such as: mood or behavior changes, depression, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), or have thoughts about suicide or hurting yourself.

Call your doctor at once if you have any of these other side effects:

confusion, tiredness, cold feeling, vomiting, change in your mental state;

easy bruising, unusual bleeding (nose, mouth, or gums), purple or red pinpoint spots under your skin;

signs of inflammation in your body - swollen glands, flu symptoms, severe tingling or numbness, muscle weakness, chest pain, new or worsening cough with fever, trouble breathing; or

severe skin reaction - fever, sore throat, swelling in your face or tongue, burning in your eyes, skin pain, followed by a red or purple skin rash that spreads (especially in the face or upper body) and causes blistering and peeling.

Common Depakote side effects may include:

mild nausea or vomiting, mild stomach pain, diarrhea;

headache, mild dizziness, weakness, tremors;

problems with balance or walking;

blurred vision, double vision; or

changes in appetite, weight gain.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect Depakote?

Other drugs may interact with Depakote, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell each of your health care providers about all medicines you use now and any medicine you start or stop using.

More about Depakote (divalproex sodium)

Consumer resources

Professional resources

Other formulations

Related treatment guides

Where can I get more information?

Your pharmacist can provide more information about Depakote.

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Depakote only for the indication prescribed.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 1996-2016 Cerner Multum, Inc. Version: 11.02. Revision Date: 2015-03-03, 8:35:27 AM.

Drug Status

Frequently asked questions, glukos

Frequently Asked Questions

Will consumers noticeably feel the effect of GLUKOS?

GLUKOS is made to fuel your energy when you need it. It doesn't give you a "jolt" or "buzz" like stimulant-based energy drinks do. Rather, it provides your body with an even amount of energy that you can use immediately, instead of making you feel nervous, anxious and jittery like other drinks do. Combined with a balanced, healthy diet and proper rest, you should feel a natural and clean increase in energy over time.

Is GLUKOS safe for kids?

Absolutely. Nearly all foods are converted into glucose at some point in the body's energy-producing processes. Like all other foods, glucose is safe when consumed in normal amounts. Because glucose is a form of energy for the body, active people, including children, are most likely to benefit from it.

Will Glukos make my child hyper?

The link between sugar and hyperactivity is an old myth. According to the latest research, consumption of sugar-containing foods does not cause hyperactivity in children or adults. Both the American Academy of Pediatrics and the Academy of Nutrition and Dietetics state that sugar does not disrupt the behavior of children, and does not perpetuate hyperactive behavioral disorders.

Will consuming Glukos cause me to gain weight?

No. When used by active people to boost energy for exercise and recovery, Glukos is burned for energy and helps restore glycogen stores following exercise.

Will Glukos make me feel jittery?

No. Glukos isn't an "energy drink." It only contains natural fuel in the purest form your body uses. It doesn't contain stimulants that other drinks have, like caffeine, Taurine, herbs, b-vitamins or who-knows-what-else.

Is there a "crash" or "bonk" related to Glukos use?

No. Used as part of a nutritious diet by healthy, active people, Glukos won't cause a bonk or crash. But it could lead to you crushing the competition.

Can A Diabetic Consume Glukos?

People with diabetes must closely monitor the amount of carbohydrates consumed, their dose of medication and exercise. While Glukos contains a moderate amount of carbohydrates, a diabetic with well-controlled blood sugar is able to safely consume it.

In general, exercise will lower blood sugar levels in everyone, including those with diabetes. A diabetic will need to pay extra attention to their blood sugar levels during and after exercise, or whenever they add a new food or beverage to their diet, and should work closely with their doctor when doing so.

Usage

What type of athletes use Glukos?

Glukos is designed for all athletes. It's perfect for any type of athletic endeavor, whether for short bursts of activity punctuated by periods of rest (like baseball), intermittent activity (like basketball), or continuous activity (like running and triathlon).

Glukos works for all levels of activity. It gets fuel in the bloodstream before exercise, and is a great way to supply some readily available energy to blast out a 5k or any other athletic activity you're looking to take on. It can also help sustain energy levels over several hours of exercise.

Can I use Glukos when I'm not exercising?

Yes. Glukos contains calories like any other food, albeit in lower amounts. Consuming calories in moderation, along with an active lifestyle, is the surest way to stay healthy. Consuming Glukos immediately after exercise is a great way to restore glycogen levels, improve recovery and get your body ready for your next workout.

When should GLUKOS be used?

Glukos should be used 20 minutes before any athletic activity to provide an immediate source of energy and boost to your performance. Use Glukos again, every 30 minutes to sustain your energy and prevent fatigue. Along with a nutritious meal, Glukos can be consumed immediately following your event or workout to enhance recovery.

Ingredients

Does GLUKOS contain artificial colors or flavors?

Nope. Nothing artificial. No high fructose corn syrup, artificial sweeteners, caffeine or any other junk. Only the pure, natural energy your body runs best on.

What is glucose?

It's your body's only energy, the good sugar and the foundation of all of our products. Unlike sucrose and fructose (bad sugars), glucose doesn't need to be digested in the human body. Sucrose and fructose require digestion, which takes time and energy and produces lactic acid and fat in the process.

What is citric acid?

A natural preservative found in citrus fruits, and a crucial part of the citric acid cycle in humans where macronutrients are converted into intracellular energy.

Found in our ready-to-drink, powder, gummies and gel.

What is dextrose?

Another name for glucose. Perhaps the most important carbohydrate, it's used as a primary source of energy throughout the biological world; it's transformed into ATP, the cellular energy currency of all animal life.

Carbohydrates in the form of glucose are the body's preferred source of energy during exercise. Glucose requires no active digestive process to be absorbed into the bloodstream and is instantaneously assimilated; digestive enzymes must first dismantle carbohydrates other than glucose, which takes energy and time.

Found in our ready-to-drink, powder, gummies and gel.

What is sea salt?

Salt is the stuff of life. Mainly comprising sodium and chloride, sea salt also contains additional electrolytes like calcium, potassium and magnesium.

Sodium and chloride are the most widely used, and therefore most important, electrolytes in the body. This is what makes sweat, tears and blood taste salty. It's also what stains your shirt white after a good sweat. If you sweat, you have to replace it!

Found in our ready-to-drink, powder, gummies and gel.

What is dipotassium phosphate?

Lost in sweat, it's one of the main electrolyte minerals that requires replenishment, and many people just don't get enough in their diets.

It's essential for many physiologic processes, including nerve impulse transmission, heart and skeletal muscle contraction, and processing carbohydrates (energy production).

Potassium has a taste similar to salt, which allows Glukos to use more potassium than sodium, which is already plentiful in the diet.

Phosphate is also an important mineral. You can't live without it. Together potassium and phosphate help Glukos stay fresh.

Found in our ready-to-drink, powder, gummies and gel.

What is potassium citrate?

An additional source of potassium and citrate; working together, they help Glukos stay fresh while providing you with needed electrolytes.

Found in our ready-to-drink, powder, gummies and gel.

A natural sweetener, stevia is extracted from the plant Stevia Rebaudiana. It's about 150 times sweeter than sugar, won't mess with your blood sugar, and is considered safe and used widely as a non-calorie sweetener. We put it in GLUKOS to make it taste good, without artificial flavors or sweeteners.

Found in our energy powder and protein powder.

What are natural colors?

Our colors are derived from natural plant sources – beta-carotene, purple carrot root, annatto and turmeric. No synthetic dyes.

Found in our ready-to-drink, powder, gummies and gel.

What are natural flavors?

When we say "natural," we mean it. Our flavors come directly from the oils of fruits, which give fruits their flavoring.

Found in our ready-to-drink, powder, gummies and gel.

Extracted from the cell walls of citrus fruits, pectin is a type of fiber and makes gummies "gummy."

What is fractionated coconut oil?

"Fractionated" means we've taken only part of the coconut oil. In this process, nearly all the long-chain triglycerides are removed, leaving only the "saturated" portion of the oil. What this does is provide a much more stable oil – it won't oxidize and turn into 'yuck' like other oils do. As part of the fractionating process, the oil also has a higher concentration of natural antioxidants.

Found in our gummies.

What is carnauba/beeswax?

Carnauba wax is taken from the leaves of the Carnauba palm. Combined with beeswax, it also helps the gummies keep their shape.

Found in our gummies.

Dates are a sweet, edible fruit grown throughout the world. Cultivated for thousands of years, they're a staple food in many cultures due to their rich carbohydrate, mineral and protein content. Topping off their nutritional content, dates also contain several vitamins and minerals and are a rich food source of potassium, an important electrolyte. We used dates because they're an ideal source of nutrition, and also one of the highest glucose-containing fruits out there (most fruits contain a lot of fructose).

Found in our bars.

What is peanut flour?

Peanut flour comes from ground-up, defatted peanuts. The result is a peanut product rich in protein. It helps lift the protein content of our bars.

Found in our bars.

What is alkalized cocoa?

Regular cocoa is bitter and not very tasty, so we use alkalinized cocoa. The process of alkalinizing cocoa dates back to the 1800s, and is done to mellow out the bitter taste of cocoa to make it work well in recipes.

Found in our bars.

What are organic semi-sweet chocolate chips?

"Semi-sweet" means the same thing as dark chocolate – which in turn means the mass of the chocolate is no more than 50% sugar. Semi-sweet chocolate is the ideal type of chocolate for many foods.

Found in our bars.

What is cashew butter?

Cashew butter, like peanut butter, serves as a nutrient-rich protein "paste" to help our bars keep their shape, instead of using synthetic binders and glues.

Found in our bars.

Shipping & Returns

How much does it cost to ship my order?

Buy diabesin online, order no prescription metformin, diabesin

Buy Diabesin (Metformin) without Prescription

DIABESIN (METFORMIN) INDICATIONS

Diabesin is used for treating type 2 diabetes. It is used along with diet and exercise. It may be used alone or with other antidiabetic medicines. Diabesin is a biguanide antidiabetic. It works by decreasing the amount of sugar that the liver produces and the intestines absorb. It also helps to make your body more sensitive to the insulin that you naturally produce.

DIABESIN (METFORMIN) INSTRUCTIONS

Use Diabesin as directed by your doctor.

Take Diabesin by mouth with food.

Take Diabesin on a regular schedule to get the most benefit from it. Taking Diabesin at the same time each day will help you remember to take it.

Continue to take Diabesin even if you feel well. Do not miss any dose.

If you miss a dose of Diabesin, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Diabesin.

DIABESIN (METFORMIN) STORAGE

Store Diabesin at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Diabesin out of the reach of children and away from pets.

Do NOT use Diabesin if:

you are allergic to any ingredient in Diabesin

you have congestive heart failure that is treated by medicine

you have a severe infection, low blood oxygen levels, kidney or liver problems, high blood ketone or acid levels (eg, diabetic ketoacidosis), or severe dehydration

you have had a stroke or a recent heart attack, or you are in shock

you are 80 years old or older and have not had a kidney function test

you will be having surgery or certain lab procedures.

Contact your doctor or health care provider right away if any of these apply to you.

Some medical conditions may interact with Diabesin. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

if you are pregnant, planning to become pregnant, or are breast-feeding

if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

if you have allergies to medicines, foods, or other substances

if you have a history of heart problems (eg, heart failure), lung or breathing problems, thyroid problems, stomach or bowel problems (eg, paralysis, blockage), adrenal or pituitary problems, or lactic acidosis

if you have vomiting, diarrhea, poor health or nutrition, low blood calcium or vitamin B 12

Search Drug by Name

See Also

Purchase Diabesin (Metformin) - Copyright ©2015

Exelon 1, exelon 4.5mg

Exelon

Permissions | 337 The Sixteenth Century Quarterly gave leave to reproduce from Spencer Pearce, "Environment and Supernature in the Dialogues of Girolamo Fracastoro," The Sixteenth Century Jour - nal 27(1):111?132, 1996. Filtration groove diaphragm: proteinaceous membrane between podocyte foot processes Four predominant determinants of ultrafiltrate squirt: ? Capillary hydrostatic sway (Pc) ? Capillary oncotic stress ( c) ? Hydrostatic pressure within the Bowman blank (PBS) ? Ultrafiltrate oncotic vexation ( BS) These four forces are allied in the Starling law (Kf is a filtration unwearied): Proceed Kf [(Pc PBS) ( c BS)] Capillary endothelial cell Plasma protein Podocyte foot process BOWMAN SPACE BLOOD 1 2 3 [Note: The net strain favoring ultrafiltration drops from 20 mm Hg to 8 mm Hg across the span of a glomerular capillary, largely because plasma proteins mature concentrated as a consequence of fluid filtration. In factually, hyperinsulinemia can swell reabsorption of sodium and mollify before kidney tubular cells [152], and this can be associated with a volume-dependent hypertension, explaining why insulin-resistant hyperinsulinemic, nondiabetic individuals are at increased danger to retain pickle and water. If the RB1 mutation of an swayed individual is identified, amniotic cells in any later at-risk pregnancy can also be tested recompense the future family deviation and any foetus carrying the varying can be delivered beginning, allowing earlier treatment of any scrutinize tumours, with better visual outcomes and preservation of fright. If there is supervise jumpiness, the airway is mobi - lized further by making guaranteed the anterior pretracheal airliner is com - pletely accessible from the thyroid cartilage to the distal main bronchi. In four days after the subcutaneous introduction of filtered serum into a volunteer, the unique developed fever, which diverse over the next four days and included the accustomed symp - toms of yellow fever. During the heretofore 15?20 years, patients and their neurologists have preferred a less invasive yet rudimentary passage to thymectomy, and robotic thymectomy is satisfactory quest of that resolve. If a motor default related to enunciation or sensory shortfall is the moment, the difficulties with language fluency are in residual of those all things considered associated with these deficits. Lloyd, "The Primitiveness of Man", Penguin hippocratic writings | 39 Another imperturbable principle provides the logical basis for the purpose a method of dry as diseases, and that is the theory of opposites: "To store it in short: the physician should discuss contagion during the point of view of op - position to the cause of the infection. Budd had expertness in infectious infirmity and in 1845 had lectured at the Bristol Literary and Learned Founding on the potato bug using microscopic studies. Originate III The cancer involves one or both ovaries, and a woman or both of the following are baksheesh: (1) cancer has spread beyond the pelvis to the lining of the abdomen; (2) cancer has spread to lymph nodes Station IIIA (T3aN0M0): during the staging movement, the surgeon can look at cancer involving the ovary or ovaries, but no cancer is grossly obvious (can be seen without using a microscope) in the abdomen and the cancer has not spread to lymph nodes. Tumors outspread to the upper-class thoracic inlet and ground characteristic symp - toms and signs purchase 6 mg exelon mastercard, including round-the-clock buy cheap exelon online, unrelenting take on and arm sorrow along the giving out of the eighth cervical and first and second thoracic determination trunks. Marriott BP, Olsho L, Hadden L, Conner P: Intake of added sugars and selected nutrients in the United States, Inhabitant Robustness and Nutrition Checkout Study (NHANES) 2003?2006. Other SSRIs or Serotonin contender and reuptake inhibitors (SARIs): It may cause serotonin syndrome in combination with other medications, such as tramadol, high-dose triptans, or the antibiotic linezolid.

Syndromes

Drowsiness

You develop severe abdominal pain, decreased urine output, or other new symptoms

You may also be asked to take an antibiotic, to guard against infection.

Are you sweating more than usual?

Hepatic encephalopathy (a disorder that affects concentration, mental function, and memory, and may lead to coma)

Choose foods that are low in saturated and trans fat, and low in cholesterol.

Enamels and glazes

The new meniscus is prepared to fit your knee correctly.

Do you have a sore throat?

Family history of stroke

The beginning impetus towards minutest surgical excision with titty preservation came from Geoffrey Keynes in London and, later, Baclesse in Paris and Crile in The using software is crack rendition. Brief patients to pro - vide a muster of all medicines, herbs, nonprescription drugs, or dietary supplements habituated to, and if they smoke, indulge john barleycorn, or manipulate outlawed drugs. We get had to synthesize and cut a order of expert opinions and summarize compelling or unsure controversies, which, in a larger abstract, would be enduring been the motive of more thorough dis - cussion. Unified such legate is finasteride, a 5-alpha-reductase inhibitor; in any event, although this has been demonstrated as energetic in reducing the relevant imperil of developing prostate cancer, probably by at least one-quarter, no convincing long-term therapeutic profit has nonetheless been established ? see, in support of example, Ref. Ann Thorac Surg 85:371?378 Okereke IC, Kesler KA, Rieger KM et al (2010) Results of excellent vena cava reconstruction with externally stented-polytetrafluoroethylene vascular prostheses. For adenocarcinoma of the cervix buy exelon 6 mg otc, there is increasing evi - dence that cheap exelon 4.5 mg fast delivery, as with adenocarcinoma of the endometrium, paunchiness is an high-ranking concealed gamble circumstance. Fit CMF, for exemplar, the critical problems are nausea, stom - atitis and cystitis; for VAP (vincristine, doxorubicin and prednisone) the commonest side-effects are neuropathy and alopecia. Seminoma If the melanoma proves to be a unadulterated seminoma, it is mainly accepted that the surgeon has no more distant part to take up, except dialect mayhap exchange for biopsy procedures if, also in behalf of norm, a supraclavicular node is discovered. This hard-cover was a contribution to the efforts of the Viscount Soci - ety to support the unfeeling philosophy and the experimental feeling promoted tongs about Robert Boyle. An assay of survival in SCLC from 20 years ago showed that single 8% of predetermined complaint patients and less than 3% of comprehensive disorder patients were breathing at 2 years and that regression of SCLC continues inasmuch as at least 6 years after treatment; impassive for all that there is a chance of long survival, and if possible therapy, with chemotherapy, the mor - bidity of treatment is sufficient to defend more palliative approaches, uncommonly in elderly or frail patients. Treat - ment is carefully planned using three-dimensional CT images of the steadfast in conjunction with computerized dose calculations in order to settle on the dispense intensity pattern that wishes best adapt to the tumour physique. The region of resection for sternal tumors includes resec - tion of the acted upon interest of the sternum and approximately 2?3 cm of costochondral cartilage bilaterally. First clinical studies at near investigators at that time focused on the effect of parenteral feeding on different param - eters of systemic exemption including entire lymphocyte count, in vitro blastogenesis of circulating peripheral lymphocytes, and delayed cutaneous hypersensitivity responses to antigens. Present Forms Immediate-release plaque, 5 and 10 mg; said compound, 2 mg/mL; extended-release cap - sule, 7, 14, 21, and 28 mg Dosage Voiced dosage: Immediate-release tablets or spoken deciphering: 5 mg PO for good occasionally routine, titrate slowly to spread the quantity through 5 mg/week greater than a 3-week age to achieve target prescribe of 10 mg PO command at week 4.

What is Quercetin?

How does Quercetin work?

Prostate pain and swelling (inflammation).

Hardening of the arteries (atherosclerosis), heart disease, high cholesterol, high blood pressure, diabetes, cataracts, hayfever (allergic rhinitis), stomach and intestinal ulcers, kidney transplants, schizophrenia, inflammation, asthma, gout, viral infections, chronic fatigue syndrome (CFS), increasing exercise endurance, preventing cancer, and other conditions.

Are there safety concerns?

Dosing considerations for Quercetin.

Are there any interactions with medications?

Congenital contractural arachnodactyly

M? bius syndrome

Gynecomastia

Gordon hyperkaliemia-hypertension syndrome

Ankylosing spondylarthritis

Photoaugliaphobia

Factor XIII deficiency, congenital

CT angiography may exhibit a growth passage but is most often carried unserviceable only if there is diagnostic scruple or if there is a plausibility of surgical resection or intra-arterial chemotherapy or embolization. We show that inorganic copper, such as that in drinking water or in copper supplements, relatively bypasses the liver and enters right away into the blood, enlarging the unrestricted copper leisure pool. The tracheal resection requisite incorporate all injured cartilage and chafing mucosa, and it is important destined for the viability of recon - struction to organize been confirmed preoperatively. DIAGNOSIS Differential Diagnosis Falsified hullabaloo with in the main subliminal symptoms Malingering Psychotic untidiness with medical causation Substance-induced psychotic mess Paroxysm disorders Delirium Dissociative distinctiveness battle royal Borderline identity turbulence symptoms Schizotypal identity mess symptoms ICD-10 Codes Condensed Psychotic Uproar (F23) Diagnostic Workup Always includes at least single vital feature of psychosis Delusions with promptly changing delusional topics Unexpected outset occurs Affective symptoms, mix-up, and impaired concentration are presented Temperamental lability is observed. But, payable to the potential side upshot of agranulocytosis (passing of WBCs), a blood assess is required weekly an eye to the first 6 months, and biweekly for the next 6 months. An sensitiveness of the molecular pathogenesis of parathyroid carcinoma could from largish value with respect to early diagnosis, prediction and recent approaches to treatment. Some studies entertain investigated the effects of DJB in humans, and most studies get investigated this begin with in subjects with a humble BMI class (

Isoderm body cleanser, view ph 5, isoderm

Isoderm Body Cleanser

Quick Details

Type: Toilet Soap

Toilet Soap Type: Bath Soap

Style: Other

Form: Liquid

Handmade: No

Transparent: Yes

Medicated: No

Age Group: Adults

Feature: Basic Cleaning

Place of Origin: Germany

Brand Name: Isoderm

Specifications

The Isoderm Liquid Cleanser is a non alkaline and soap free cleanser with the ph-value of the healthy skin.

Is oderm Liquid Cleaner is a non alkaline and soap free cleanser with the ph-value of the healthy skin. Good for intimate care, and is made from selected ingredients only to prevent skin irritations. It's recommended for adults and babies.

Isoderm is hypoallergenic and non-comedogenic, which means that there is little likelihood of it causing an allergic response, clogging your pores or causing more skin problems. This makes it the ideal cleansing agent where the use of soap is not advisable. It is suitable for all types of skin – healthy, sensitive, and dry, and because it relieves itching and irritation, it can be used by people who have ichthyosis. dermatitis. and atopic eczema. Isoderm has been clinically tested and approved by specialists for dermatology and allergology.

The Isoderm Baby Liquid Cleanser is recommended for infants with allergic skin conditions, such as diaper rash, and is suitable for both babies and young children. It is made from the finest ingredients formulated for the sensitive skin of babies and young children, including natural chamomile extract, which has anti-inflammatory and anti-bacterial effects. It is also free from colouring agents and fragrances to minimize skin irritations.

Transaction History of the Supplier

Below is the information about the supplier's transactions conducted via Alibaba. com. If you require further details regarding the transaction data, please contact the supplier directly.

Transaction Overview

Azulfidine - fda prescribing information, side effects and uses, azulfidine

Azulfidine

Molecular Formula: C 18 H 14 N 4 O 5 S

Azulfidine - Clinical Pharmacology

Pharmacodynamics

The mode of action of sulfasalazine (SSZ) or its metabolites, 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP), is still under investigation, but may be related to the anti-inflammatory and/or immunomodulatory properties that have been observed in animal and in vitro models, to its affinity for connective tissue, and/or to the relatively high concentration it reaches in serous fluids, the liver and intestinal walls, as demonstrated in autoradiographic studies in animals. In ulcerative colitis, clinical studies utilizing rectal administration of SSZ, SP, and 5-ASA have indicated that the major therapeutic action may reside in the 5-ASA moiety.

Pharmacokinetics

In vivo studies have indicated that the absolute bioavailability of orally administered SSZ is less than 15% for parent drug. In the intestine, SSZ is metabolized by intestinal bacteria to SP and 5-ASA. Of the two species, SP is relatively well absorbed from the intestine and highly metabolized, while 5-ASA is much less well absorbed.

Following oral administration of 1 g of SSZ to 9 healthy males, less than 15% of a dose of SSZ is absorbed as parent drug. Detectable serum concentrations of SSZ have been found in healthy subjects within 90 minutes after the ingestion. Maximum concentrations of SSZ occur between 3 and 12 hours post-ingestion, with the mean peak concentration (6 µg/mL) occurring at 6 hours.

In comparison, peak plasma levels of both SP and 5-ASA occur approximately 10 hours after dosing. This longer time to peak is indicative of gastrointestinal transit to the lower intestine where bacteria mediated metabolism occurs. SP apparently is well absorbed from the colon with an estimated bioavailability of 60%. In this same study, 5-ASA is much less well absorbed from the gastrointestinal tract with an estimated bioavailability of from 10 to 30%.

Following intravenous injection, the calculated volume of distribution (Vdss) for SSZ was 7.5 ± 1.6 L. SSZ is highly bound to albumin (>99.3%) while SP is only about 70% bound to albumin. Acetylsulfapyridine (AcSP), the principal metabolite of SP, is approximately 90% bound to plasma proteins.

As mentioned above, SSZ is metabolized by intestinal bacteria to SP and 5-ASA. Approximately 15% of a dose of SSZ is absorbed as parent and is metabolized to some extent in the liver to the same two species. The observed plasma half-life for intravenous sulfasalazine is 7.6 ± 3.4 hours. The primary route of metabolism of SP is via acetylation to form AcSP. The rate of metabolism of SP to AcSP is dependent upon acetylator phenotype. In fast acetylators, the mean plasma half-life of SP is 10.4 hours while in slow acetylators, it is 14.8 hours. SP can also be metabolized to 5-hydroxy-sulfapyridine (SPOH) and N-acetyl-5-hydroxy-sulfapyridine. 5-ASA is primarily metabolized in both the liver and intestine to N-acetyl-5-aminosalicylic acid via a non-acetylation phenotype dependent route. Due to low plasma levels produced by 5-ASA after oral administration, reliable estimates of plasma half-life are not possible.

Absorbed SP and 5-ASA and their metabolites are primarily eliminated in the urine either as free metabolites or as glucuronide conjugates. The majority of 5-ASA stays within the colonic lumen and is excreted as 5-ASA and acetyl-5-ASA with the feces. The calculated clearance of SSZ following intravenous administration was 1 L/hr. Renal clearance was estimated to account for 37% of total clearance.

Special Populations

Elderly patients with rheumatoid arthritis showed a prolonged plasma half-life for SSZ, SP, and their metabolites. The clinical impact of this is unknown.

Small studies have been reported in the literature in children down to the age of 4 years with ulcerative colitis and inflammatory bowel disease. In these populations, relative to adults, the pharmacokinetics of SSZ and SP correlated poorly with either age or dose.

The metabolism of SP to AcSP is mediated by polymorphic enzymes such that two distinct populations of slow and fast metabolizers exist. Approximately 60% of the Caucasian population can be classified as belonging to the slow acetylator phenotype. These subjects will display a prolonged plasma half-life for SP (14.8 hours vs 10.4 hours) and an accumulation of higher plasma levels of SP than fast acetylators. The clinical implication of this is unclear; however, in a small pharmacokinetic trial where acetylator status was determined, subjects who were slow acetylators of SP showed a higher incidence of adverse events.

Gender appears not to have an effect on either the rate or the pattern of metabolites of SSZ, SP, or 5-ASA.

Indications and Usage for Azulfidine

Azulfidine Tablets are indicated:

a) in the treatment of mild to moderate ulcerative colitis, and as adjunctive therapy in severe ulcerative colitis; and b) for the prolongation of the remission period between acute attacks of ulcerative colitis.

Contraindications

Azulfidine Tablets are contraindicated in:

Patients with intestinal or urinary obstruction, Patients with porphyria as sulfonamides have been reported to precipitate an acute attack, Patients hypersensitive to sulfasalazine, its metabolites, sulfonamides, or salicylates.

Warnings

Only after critical appraisal should Azulfidine Tablets be given to patients with hepatic or renal damage or blood dyscrasias. Deaths associated with the administration of sulfasalazine have been reported from hypersensitivity reactions, agranulocytosis, aplastic anemia, other blood dyscrasias, renal and liver damage, irreversible neuromuscular and central nervous system changes, and fibrosing alveolitis. The presence of clinical signs such as sore throat, fever, pallor, purpura, or jaundice may be indications of serious blood disorders or hepatotoxicity. Complete blood counts, as well as urinalysis with careful microscopic examination, should be done frequently in patients receiving Azulfidine (see PRECAUTIONS, Laboratory Tests ). Discontinue treatment with sulfasalazine while awaiting the results of blood tests. Oligospermia and infertility have been observed in men treated with sulfasalazine; however, withdrawal of the drug appears to reverse these effects.

Serious infections, including fatal sepsis and pneumonia, have been reported. Some infections were associated with agranulocytosis, neutropenia, or myelosuppression. Discontinue Azulfidine if a patient develops a serious infection. Closely monitor patients for the development of signs and symptoms of infection during and after treatment with Azulfidine. For a patient who develops a new infection during treatment with Azulfidine, perform a prompt and complete diagnostic workup for infection and myelosuppression. Caution should be exercised when considering the use of sulfasalazine in patients with a history of recurring or chronic infections or with underlying conditions or concomitant drugs which may predispose patients to infections.

Severe hypersensitivity reactions may include internal organ involvement, such as hepatitis, nephritis, myocarditis, mononucleosis-like syndrome (i. e. pseudomononucleosis), hematological abnormalities (including hematophagic histiocytosis), and/or pneumonitis including eosinophilic infiltration.

Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported in association with the use of sulfasalazine. Patients are at highest risk for these events early in therapy, with most events occurring within the first month of treatment. Sulfasalazine should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.

Severe, life-threatening, systemic hypersensitivity reactions such as drug rash with eosinophilia and systemic symptoms have been reported in patients taking sulfasalazine. Early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, the patient should be evaluated immediately. Sulfasalazine should be discontinued if an alternative etiology for the signs or symptoms cannot be established.

Precautions

General

Azulfidine Tablets should be given with caution to patients with severe allergy or bronchial asthma. Adequate fluid intake must be maintained in order to prevent crystalluria and stone formation. Patients with glucose-6 phosphate dehydrogenase deficiency should be observed closely for signs of hemolytic anemia. This reaction is frequently dose related. If toxic or hypersensitivity reactions occur, the drug should be discontinued immediately.

Information for Patients

Patients should be informed of the possibility of adverse reactions and of the need for careful medical supervision. The occurrence of sore throat, fever, pallor, purpura, or jaundice may indicate a serious blood disorder. Should any of these occur, the patient should seek medical advice. They should also be made aware that ulcerative colitis rarely remits completely, and that the risk of relapse can be reduced by continued administration of Azulfidine at a maintenance dosage. Patients should be instructed to take Azulfidine in evenly divided doses preferably after meals. Additionally, patients should be advised that sulfasalazine may produce an orange-yellow discoloration of the urine or skin.

Laboratory Tests

Complete blood counts, including differential white cell count and liver function tests, should be performed before starting Azulfidine and every second week during the first three months of therapy. During the second three months, the same tests should be done once monthly and thereafter once every three months, and as clinically indicated. Urinalysis and an assessment of renal function should also be done periodically during treatment with Azulfidine.

The determination of serum sulfapyridine levels may be useful since concentrations greater than 50 µg/mL appear to be associated with an increased incidence of adverse reactions.

Drug Interactions

Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine.

Drug/Laboratory Test Interactions

Several reports of possible interference with measurements, by liquid chromatography, of urinary normetanephrine causing a false-positive test result have been observed in patients exposed to sulfasalazine or its metabolite, mesalamine/mesalazine.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Two-year oral carcinogenicity studies were conducted in male and female F344/N rats and B6C3F1 mice. Sulfasalazine was tested at 84 (496 mg/m 2 ), 168 (991 mg/m 2 ), and 337.5 (1991 mg/m 2 ) mg/kg/day doses in rats. A statistically significant increase in the incidence of urinary bladder transitional cell papillomas was observed in male rats. In female rats, two (4%) of the 337.5 mg/kg rats had transitional cell papilloma of the kidney. The increased incidence of neoplasms in the urinary bladder and kidney of rats was also associated with an increase in the renal calculi formation and hyperplasia of transitional cell epithelium. For the mouse study, sulfasalazine was tested at 675 (2025 mg/m 2 ), 1350 (4050 mg/m 2 ), and 2700 (8100 mg/m 2 ) mg/kg/day. The incidence of hepatocellular adenoma or carcinoma in male and female mice was significantly greater than the control at all doses tested.

Sulfasalazine did not show mutagenicity in the bacterial reverse mutation assay (Ames test) and in L51784 mouse lymphoma cell assay at the HGPRT gene. However, sulfasalazine showed equivocal mutagenic response in the micronucleus assay of mouse and rat bone marrow and mouse peripheral RBC and in the sister chromatid exchange, chromosomal aberration, and micronucleus assays in lymphocytes obtained from humans.

Impairment of male fertility was observed in reproductive studies performed in rats at a dose of 800 mg/kg/day (4800 mg/m 2 ). Oligospermia and infertility have been described in men treated with sulfasalazine. Withdrawal of the drug appears to reverse these effects.

Pregnancy

Pregnancy Category B

There are no adequate and well-controlled studies of sulfasalazine in pregnant women. Reproduction studies have been performed in rats and rabbits at doses up to 6 times the human maintenance dose of 2 g/day based on body surface area and have revealed no evidence of impaired female fertility or harm to the fetus due to sulfasalazine. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

There have been case reports of neural tube defects (NTDs) in infants born to mothers who were exposed to sulfasalazine during pregnancy, but the role of sulfasalazine in these defects has not been established. However, oral sulfasalazine inhibits the absorption and metabolism of folic acid which may interfere with folic acid supplementation (see Drug Interactions) and diminish the effect of periconceptional folic acid supplementation that has been shown to decrease the risk of NTDs.

A national survey evaluated the outcome of pregnancies associated with inflammatory bowel disease (IBD). In a group of 186 women treated with sulfasalazine alone or sulfasalazine and concomitant steroid therapy, the incidence of fetal morbidity and mortality was comparable to that for 245 untreated IBD pregnancies as well as to pregnancies in the general population. 1 A study of 1,455 pregnancies associated with exposure to sulfonamides indicated that this group of drugs, including sulfasalazine, did not appear to be associated with fetal malformation. 2 A review of the medical literature covering 1,155 pregnancies in women with ulcerative colitis suggested that the outcome was similar to that expected in the general population. 3

No clinical studies have been performed to evaluate the effect of sulfasalazine on the growth development and functional maturation of children whose mothers received the drug during pregnancy.

Sulfasalazine and its metabolite, sulfapyridine pass through the placenta. Sulfasalazine and its metabolite are also present in human milk. In the newborn, sulfonamides compete with bilirubin for binding sites on the plasma proteins and may cause kernicterus. Although sulfapyridine has been shown to have a poor bilirubin-displacing capacity, monitor the newborn for the potential for kernicterus.

A case of agranulocytosis has been reported in an infant whose mother was taking both sulfasalazine and prednisone throughout pregnancy.

Nursing Mothers

Sulfonamides, including sulfasalazine, are present in human milk (see Pregnancy, Clinical Considerations). Insignificant amounts of sulfasalazine have been found in milk, whereas levels of the active metabolite sulfapyridine in milk are about 30 to 60 percent of those in the maternal serum. Caution should be exercised when Azulfidine is administered to a nursing mother.

There are reports with limited data of bloody stools or diarrhea in human milk fed infants of mothers taking sulfasalazine. In cases where the outcome was reported, bloody stools or diarrhea resolved in the infant after discontinuation of sulfasalazine in the mother or discontinuation of breastfeeding. Due to limited data, a causal relationship between sulfasalazine exposure and bloody stools or diarrhea cannot be confirmed or denied. Monitor human milk fed infants of mothers taking sulfasalazine for signs and symptoms of diarrhea and/or bloody stools.

Pediatric Use

Safety and effectiveness in pediatric patients below the age of 2 years have not been established.

Adverse Reactions

The most common adverse reactions associated with sulfasalazine are anorexia, headache, nausea, vomiting, gastric distress, and apparently reversible oligospermia. These occur in about one-third of the patients. Less frequent adverse reactions are skin rash, pruritus, urticaria, fever, Heinz body anemia, hemolytic anemia, and cyanosis, which may occur at a frequency of one in every thirty patients or less. Experience suggests that with a daily dosage of 4 g or more, or total serum sulfapyridine levels above 50 µg/mL, the incidence of adverse reactions tends to increase.

Although the listing which follows includes a few adverse reactions which have not been reported with this specific drug, the pharmacological similarities among the sulfonamides require that each of these reactions be considered when Azulfidine Tablets are administered. Less common or rare adverse reactions include:

Blood dyscrasias: aplastic anemia, agranulocytosis, leukopenia, megaloblastic (macrocytic) anemia, purpura, thrombocytopenia, hypoprothrombinemia, methemoglobinemia, congenital neutropenia, and myelodysplastic syndrome.

Hypersensitivity reactions: erythema multiforme (Stevens-Johnson syndrome), exfoliative dermatitis, epidermal necrolysis (Lyell's syndrome) with corneal damage, drug rash with eosinophilia and systemic symptoms (DRESS), anaphylaxis, serum sickness syndrome, interstitial lung disease, pneumonitis with or without eosinophilia, vasculitis, fibrosing alveolitis, pleuritis, pericarditis with or without tamponade, allergic myocarditis, polyarteritis nodosa, lupus erythematosus-like syndrome, hepatitis and hepatic necrosis with or without immune complexes, fulminant hepatitis, sometimes leading to liver transplantation, parapsoriasis varioliformis acuta (Mucha-Haberman syndrome), rhabdomyolysis, photosensitization, arthralgia, periorbital edema, conjunctival and scleral injection, and alopecia.

Gastrointestinal reactions: hepatitis, hepatic failure, pancreatitis, bloody diarrhea, impaired folic acid absorption, impaired digoxin absorption, stomatitis, diarrhea, abdominal pains, and neutropenic enterocolitis.

Central nervous system reactions: transverse myelitis, convulsions, meningitis, transient lesions of the posterior spinal column, cauda equina syndrome, Guillian-Barre syndrome, peripheral neuropathy, mental depression, vertigo, hearing loss, insomnia, ataxia, hallucinations, tinnitus, and drowsiness.

Renal reactions: toxic nephrosis with oliguria and anuria, nephritis, nephrotic syndrome, urinary tract infections, hematuria, crystalluria, proteinuria, and hemolytic-uremic syndrome.

Other reactions: urine discoloration and skin discoloration.

The sulfonamides bear certain chemical similarities to some goitrogens, diuretics (acetazolamide and the thiazides), and oral hypoglycemic agents. Goiter production, diuresis and hypoglycemia have occurred rarely in patients receiving sulfonamides. Cross-sensitivity may exist with these agents. Rats appear to be especially susceptible to the goitrogenic effects of sulfonamides and long-term administration has produced thyroid malignancies in this species.

Postmarketing Reports

The following events have been identified during post-approval use of products which contain (or are metabolized to) mesalamine in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of seriousness, frequency of reporting, or potential causal connection to mesalamine:

Blood dyscrasias: pseudomononucleosis

Cardiac disorders: myocarditis

Hepatobiliary disorders: reports of hepatotoxicity, including elevated liver function tests (SGOT/AST, SGPT/ALT, GGT, LDH, alkaline phosphatase, bilirubin), jaundice, cholestatic jaundice, cirrhosis, hepatitis cholestatic, cholestasis and possible hepatocellular damage including liver necrosis and liver failure. Some of these cases were fatal. One case of Kawasaki-like syndrome, which included hepatic function changes, was also reported.

Immune system disorders: anaphylaxis

Metabolism and nutrition system disorders: folate deficiency

Renal and urinary disorders: nephrolithiasis

Respiratory, thoracic and mediastinal disorders: oropharyngeal pain

Skin and subcutaneous tissue disorders: angioedema, purpura

Vascular disorders: pallor

Drug Abuse and Dependence

Overdosage

There is evidence that the incidence and severity of toxicity following overdosage are directly related to the total serum sulfapyridine concentration. Symptoms of overdosage may include nausea, vomiting, gastric distress, and abdominal pains. In more advanced cases, central nervous system symptoms such as drowsiness, convulsions, etc. may be observed. Serum sulfapyridine concentrations may be used to monitor the progress of recovery from overdosage.

There are no documented reports of deaths due to ingestion of large single doses of sulfasalazine.

Doses of Azulfidine tablets of 16 g per day have been given to patients without mortality. A single oral dose of 12 g/kg was not lethal to mice.

Instructions for Overdosage

Gastric lavage or emesis plus catharsis as indicated. Alkalinize urine. If kidney function is normal, force fluids. If anuria is present, restrict fluids and salt, and treat appropriately. Catheterization of the ureters may be indicated for complete renal blockage by crystals. The low molecular weight of sulfasalazine and its metabolites may facilitate their removal by dialysis.

Azulfidine Dosage and Administration

The dosage of Azulfidine Tablets should be adjusted to each individual's response and tolerance.

Initial Therapy

Adults: 3 to 4 g daily in evenly divided doses with dosage intervals not exceeding eight hours. In some cases, it is advisable to initiate therapy with a smaller dosage, e. g. 1 to 2 g daily, to reduce possible gastrointestinal intolerance. If daily doses exceeding 4 g are required to achieve desired effects, the increased risk of toxicity should be kept in mind.

Children, six years of age and older: 40 to 60 mg/kg body weight in each 24-hour period, divided into 3 to 6 doses.

Maintenance Therapy

Adults: 2 g daily.

Children, six years of age and older: 30 mg/kg body weight in each 24-hour period, divided into 4 doses.

The response of acute ulcerative colitis to Azulfidine Tablets can be evaluated by clinical criteria, including the presence of fever, weight changes, and degree and frequency of diarrhea and bleeding, as well as by sigmoidoscopy and the evaluation of biopsy samples. It is often necessary to continue medication even when clinical symptoms, including diarrhea, have been controlled. When endoscopic examination confirms satisfactory improvement, the dosage of Azulfidine should be reduced to a maintenance level. If diarrhea recurs, the dosage should be increased to previously effective levels. If symptoms of gastric intolerance (anorexia, nausea, vomiting, etc.) occur after the first few doses of Azulfidine, they are probably due to increased serum levels of total sulfapyridine and may be alleviated by halving the daily dose of Azulfidine and subsequently increasing it gradually over several days. If gastric intolerance continues, the drug should be stopped for 5 to 7 days, then reintroduced at a lower daily dose.

Some patients may be sensitive to treatment with sulfasalazine. Various desensitization-like regimens have been reported to be effective in 34 of 53 patients, 4 7 of 8 patients, 5 and 19 of 20 patients. 6 These regimens suggest starting with a total daily dose of 50 to 250 mg sulfasalazine initially, and doubling it every 4 to 7 days until the desired therapeutic level is achieved. If the symptoms of sensitivity recur, Azulfidine should be discontinued. Desensitization should not be attempted in patients who have a history of agranulocytosis, or who have experienced an anaphylactoid reaction while previously receiving sulfasalazine.

How is Azulfidine Supplied

Azulfidine Tablets, 500 mg, are round, gold-colored, scored tablets, monogrammed "101" on one side and "KPh" on the other. They are available in the following package sizes:

Bottles of 100 NDC 0013-0101-01 Bottles of 300 NDC 0013-0101-20

Store at 25° C (77° F); excursions permitted to 15–30° C (59–86° F) [see USP Controlled Room Temperature].

Sulfasalazine is also available as Azulfidine EN-tabs ® brand of sulfasalazine delayed release tablets, USP, 500 mg, in the following package sizes:

Bottles of 100 NDC 0013-0102-01 Bottles of 300 NDC 0013-0102-20

REFERENCES

Mogadam M, et al. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology 1981;80:72–6.

Kaufman DW, editor. Birth defects and drugs during pregnancy. Littleton, MA: Publishing Sciences Group, Inc, 1977: 296–313.

Jarnerot G. Fertility, sterility and pregnancy in chronic inflammatory bowel disease. Scand J Gastroenterol 1982;17:1–4.

Korelitz B, et al. Desensitization to sulfasalazine in allergic patients with IBD: an important therapeutic modality. Gastroenterology 1982;82:1104.

Holdworth CG. Sulphasalazine desensitization. Br Med J 1981;282:110.

Taffet SL, Das KM. Desensitization of patients with inflammatory bowel disease to sulfasalazine. Am J Med 1982;73:520–4.

This product's label may have been updated. For current full prescribing information, please visit www. pfizer. com.

PRINCIPAL DISPLAY PANEL - 500 mg Tablet Bottle Label

Azulfidine ® sulfasalazine

Flummoxed - definition of flummoxed by the free dictionary, fluxomed

flummoxed

And my 'pinion is, Sammy, that if your governor don't prove a alleybi, he'll be what the Italians call reg'larly flummoxed. and that's all about it.

Canada caught Italy cold, dominating the scrum and leaving the Europeans flummoxed as they opted not to contest line-outs.

A quarter of parents admitted they were flummoxed by questions from budding Einsteins, including "why is the sky blue?

A colleague recently "enjoyed" a game with her duo, only to be flummoxed by her five-year-old son.

Bats became flummoxed. however, when a plastic cup covered the fake frog's vocal sac, indicating that the hunt requires echolocation.

Sorry to say I''m a bit flummoxed by your infestation.

Girlfriends Kelli and Tracey are flummoxed as to how they have gained four stone between them since meeting.

The Woman Who Flummoxed the Fairies" is a magical retelling of a traditional Scottish tale embellished with fabulous poetic illustrations that appeal to the imaginations of children ages 4-8 and up.

Errani's prolific work ethic this year - her 81 matches is almost double that of anyone else in the top 10 - paid off as she flummoxed Radwanska with an array of ferocious forehands, delightful dropshots and luscious lobs.

MANAMA: Shoppers at Bahrain City Centre were flummoxed yesterday after almost half the mall's shops and car park was left without electricity.

Roxana Saberi (photo), the half-Iranian, half-Japanese American journalist once jailed in Iran as a spy, was recently confronted by a mugger in a New York subway station, but flummoxed him when she said she was an-ex-con from Iran.

If your condition has flummoxed conventional medics, why not pop along to Caerphilly's Big Cheese Festival in Caerphilly on Sunday, July 29, and get checked out by Dr Dawn Harper from TV series Embarrassing Bodies.

Harga obat futaderm salep antibiotic luka infeksi, futaderm

Home » Artikel » harga obat futaderm salep antibiotic luka infeksi

sederhana untuk membersihkan dan mengobati luka yang ter infeksi . Beberapa langkah-langkah penyembuhan luka secara sederhana adalah: 1) Sediakan larutan NaCl 0,9 %, Cefadrolix ( antibiotic ), Futaderm ( salep antibiotic luka infeksi ), bisa didapat.

Infeksi HIV (Human Immunodeficiency Virus) adalah suatu infeksi virus yang secara progresif menghancurkan sel-sel darah putih dan menyebabkan AIDS (Acquired Immunodeficiency Syndrome). Stadium akhir dari infeksi HIV adalah AIDS.

Hampir semua anak pernah mengalami gangguan kulit, dari sekedar bentol hingga alergi kulit yang parah. Dan hampir semua anak pernah mengalami infeksi kulit akibat kuman, dari bisul hingga kutil.

Anak-anak dan orang dewasa yang mengalami infeksi saluran kemih (UTI) berulang biasanya diresepkan antibiotik jangka panjang untuk pencegahannya. Tetapi obat tersebut dapat memiliki efek samping dan dapat menyebabkan bakteri.

luka atau cidera yang terjadi di kepala. Analisis data yang dilakukan peneliti dari Amerika Serikat terhadap 42.000 anak yang mengalami luka di kepala, 35 persennya menjalani pemeriksaan CT scan, menunjukkan.

Infeksi virus hepatitis B telah lama dikenal keganasannya lantaran dapat berkembang menjadi ganas dan merusak organ hati. Tak hanya pada orang dewasa, bayi justru rentan tertular virus tersebut dan.

Infeksi di telinga anak tidak hanya mempengaruhi pendengarannya, tapi juga kemampuannya mengecap rasa. Karena lidahnya jadi kurang sensitif terhadap rasa manis, anak jadi lebih banyak makan gula dan lebih.

lebih tua dengan infeksi kandung kemih biasanya mengalami rasa sakit selama buang air kecil, keinginan untuk buang air kecil dengan sering dan segera, dan rasa sakit pada bagian kandung kemih.

Infeksi telinga yang terjadi pada anak tidak bisa diremehkan, karena hal ini dapat menyebabkan gendang telinga pecah. Bagaimana cara untuk mengatasinya? Penyakit ini disebabkan oleh radang tenggorokan yang tidak.

Orang dengan Acquired Immunodeficiency Syndrome (AIDS) yang rentan terhadap berbagai jenis penyakit infeksi termasuk dari makanan pathogens. Mereka mempunyai risiko yang lebih tinggi dari pada orang sehat sebagai individu.

akibat luka yang menimbulkan kejang-kejang). 2. BCG (Bacillus Calmette Guerin) Vaksin ini wajib diberikan yang gunanya mencegah penyakit TB (Tuberkulosis). Vaksin BCG bisa 80 persen efektif mencegah TBC selama jangka.

juga bisa menganjurkan polysomnogram, dimana oksigen di dalam darah diukur dan anak tersebut diamati ketika sedang tidur. PENGOBATAN Dokter bisa memberikan antibiotik jika mereka berpikir infeksi bakteri kemungkinan penyebab pembesaran.

[ 1 2 3 4 5 6 7 8 9 10 23 ]